

			ACADEMIC PLANNER (MUH	IS 20 DATCH Dhase III		
			ACADEMIC PLANNER (MOR	15-36 BATCH Pliase-II)		
		MEDICINE	OB/GY	SURGERY	COMMUNITY MED	
		PHARMACOLOGY	PATHOLOGY	MICROBIOLOGY	FM & T	
		AETCOM	CLINICAL POSTING	SPORTS & ECA		
				March-2023	3	
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00
01.03.2023	WEDNESDAY	PA-L PA1.1 Describe the role of pathologist in diagnosis and management of disease PA 1.2 Enumerate common definitions and terms used in pathology PA1.3 Describe the history and evolution of Pathology	CLINICAL POSTING	MI-P MI1.1 Introduction, History of microbiology, Introduction to bacteria, viruses & Bacteriophages, fungi, parasites, Nomenclature & Classification Bacteria -	PA-P SGD -{ Batch A} PA1.1 Describe the role of pathologist in diagnosis and management of disease PA 1.2 Enumerate common definitions and terms used in pathology PA1.3 Describe the history and evolution of Pathology	MI-P SGD MI1.2 Introduction to Microbial World/Microscopy
02.03.2023	THURSDAY	PA-L PA2.1 Demonstrate knowledge of the causes, mechanisms,types and effects of cell injury and their clinical sinificance. PA 2.2 Describe the etiology of cell injury.Distinguish between reversible-inreversible injury: mechanisms; morphology of cell injury		PH-P (Batch A+B) – 1.1 Introduction to Pharmacology	PA-P SGD (Batch B) PA1.1 Describe the role of pathologist in diagnosis and management of disease PA 1.2 Enumerate common definitions and terms used in pathology PA1.3 Describe the history and evolution of Pathology	MI-P SGD MI1.2 Introduction to Microbial World/Microscopy
03.03.2024	FRIDAY	MI-L MI1.1 Physiology of bacteria &Normal flora MI1.1, MI1.3 Host parasite relationship		PH-L - 1.1 + 1.9. 1.1 Define and describe the principles of Pharmacology and Pharmacotherapeutics 1.9 Describe nomenclature of drugs i.e. generic, branded drugs	CM-P (Batch B) CM 3.1 & 3.2 Water disinfectants, water-problem solving, interpretation of water analysis report	Lecture-1 FM 1.1, 1.3& 1.4- Introductin of Legal Procedure
04.03.2023	SATURDAY	SUR-L Metabolic response to injury. SU1,1 Describe Basic concepts of homeostasis, enumerate the metabolic changes in linjury and their mediators. SU1,2Describe the factors that affect the metabolic response to injury, SU1,3Describe basic concepts of perioperative care.	10-11 MI-L MI1.1 Standard And Additional Precautions 11-12 MED-L IM 4.1 to 4.5 Introduction to Fever, Pathophysiology, Causes- 12-1 OBG-L-OG 2.1 Anatomy of the female reproductive tract, 1	PA-L. PA 2.3 Intracellular accumulation of fats,proteins,carbohydrates, pigments	PH- P -4.1(Batch B) Administered drugs through various routes in simulated environment using manikins (Drug Administration by routes in mannequins)	PA-P SGD (Batch A) PA2.1 Demonstrate knowledge of the causes, mechanisms,types and effects of cell injur, and their clinical sinificance, PA 2.2 Describe the titology of cell injury.Distinguish between reversible-irreversible injury: mechanisms; morpholog of cell injuryPA 2.3 Intracellular accumulation of fats,proteins,carbohydrates, pigments
05.03.2023				SUNDAY		
06.03.2023	MONDAY	PH-L - 1.11 Describe Various routes of drug administration, eg., oral, SC, IV, IM, SL	CLINICAL POSTING	F M 1,5,1.6 & 1.7- Lecture- 2 Legal procedure	PH- P -4.1(Batch A) Administered drugs through various routes in simulated environment using manikins (Drug Administration by routes in mannequins)	PA-P SGD (Batch B)PA2.1 Demonstrate knowledge of the causes, mechanisms,types and effects of cell injur and their clinical sinificance. PA 2.2 Describe the etiology of cell injury.Distinguish between reversible-irreversible injury: mechanisms; morpholog of cell injuryPA 2.3 Intracellular accumulation of fats,proteins,carbohydrates, pigments
07.03.2023	TUESDAY			DHULIWANDAN		

08.03.2023	WEDNESDAY	PA -L P A 2.4 Describe and discuss cell death - types,mechanisms, necrosis,apoptosis,autolysis.PA 2.7 Describe and discuss mechanisms of cellular aging and apoptosis.	CLINICAL POSTING	MI-P M 1.1, M 8.9 M 8.10, Lab diagnosis of bacterial infections	PA-P SGD (Batch A) PA 23.1 (1) Describe abnormal urinary findings in disease states and identify and describe common urinary abnormalities in clinical specimen	MI-P MI8.11, MI8.12 MI8.13, MI8.14 SGD Handling ,Collection & Transport of specimen
09.03.2023	THURSDAY	PA-L PA 2.5 Describe and discuss pathologic calcifications, gangrene. PA 2.6 Describe and discuss cellular adaptations: Atrophy,Hypertrophy,Hyperplasia,Metaplasia,Dysplasia		PH-P - (Batch A+B) 1.3 Enumerate and identify drug formulation s and drug delivery systems	PA-P SGD (Batch B) PA 23.1 (1) Describe abnormal urinary findings in disease states and identify and describe common urinary abnormalities in clinical specimen	FM-P SGD -1-FM14.20- Skill in Forensic Medicine (Batch A)
10.03.2023	FRIDAY	MI-L MI1.1 General Properties Classification, and cultivation of Viruses		PH-L - 1.4 Describe absorption, distribution, metabolism & excretion of drugs	CM-P (Batch A) CM 3.1 & 3.2 Water disinfectants, water-problem solving, interpretation of water analysis report	MI8.11, MI8.12 MI8.13, MI8.14 SGD Handling ,Collection & Transport of specimen
11.03.2023	SATURDAY	SUR-LWound healing and wound care SU5.1 Describe normal wound healing and factors affecting healing. SU5.3 Differentiate the various types of wounds, plan and observemanagement	10-11 MI-L MI1.1 General Properties and Classification of fungi and paras 11-12 MED-L IM 4.6; 4.15; 4.22 to 4.26 Malaria 12-1 OBG-L OG 3.1.Physiology of menstruation	i PA-L PA 3.1 Describe the pathogenesis and pathology of Amyloidosis	PH- P -4.1(Batch B) Administered drugs through various routes in simulated environment using manikins (Drug Administration by routes in mannequins)	PA-P SGD (Batch A)P A 2.4 Describe and discuss cell death - types, mechanisms, necrosis, apoptosis, autolysis. PA 2.7 Describe and discuss mechanisms of cellular aging and apoptosis.PA 2.5 Describe and discuss pathologic calcifications, gangrene. PA 2.6 Describe and discuss cellular adaptations: Atrophy,Hypertrophy,Hyperplasia,Metaplasia, Dysplasia .PA 2.8 Identify and describe various forms of cell injuries, their manifestations and consequences in gross and microscopic specimens
12.03.2023				SUNDAY		
13.03.2023	MONDAY	PH-L - 1.4 Describe absorption, distribution, metabolism & excretion of drugs	CLINICAL POSTING	FM 1.2 SDL-1 Introduction , describe history of Forensic Medicine	PH- P -4.1 (Batch A) Administered drugs through various routes in simulated environment using manikins (Drug Administration by routes in mannequins)	PA-P SGD (Batch B) 2.4 Describe and discuss cell death - types, mechanisms, necrosis, apoptosis, autolysis. PA 2.7 Describe and discuss mechanisms of cellular aging and apoptosis.PA 2.5 Describe and discuss pathologic calcifications, gangrene. PA 2.6 Describe and discuss cellular adaptations : Atrophy, Hypertrophy, Hyperplasia, Metaplasia, Dysplasia .PA 2.8 Identify and describe various forms of cell injuries, their manifestations and consequences in
14.03.2023	TUESDAY	PH-L - 1.4 Describe absorption, distribution, metabolism & excretion of drugs		CM-L CM 3.2 Water I- Introduction to environmental sanitation and safe & wholesome water, water related diseases	CM-P (Batch A) CM 3.2 Visit to water filtration plant	FM-1.1,13 &1.4 SGD :Skill FMT, FM 14.20 (Batch- B)
15.03.2023	WEDNESDAY	PA-L PA 4.1 Define and describe the general features of acute and chronic inflammation including stimuli, vascular and cellular events.		MI-P MI1.1, MI8.9 MI8.10 Lab diagnosis of Viruses/fungi/parasites infections	PA-P SGD (Batch A)PA 23.1 (II) Describe abnormal urinary findings in disease states and identify and describe common urinary abnormalities in clinical specimen PA 3.1 Describe the pathogenesis and pathology of Amyloidosis PA 3.2 (dentify and describe amyloidosis in a pathology specimen	MI-P SGD MI1.1 Identification of Bacteria (MOPRHOLOGY)+ Laboratory Diagnosis of viral infections
16.03.2023	THURSDAY			ANNUAL DAY		

17.03.2023	FRIDAY		ANNUAL DAY						
18.03.2023	SATURDAY			ANNUAL DAY					
19.03.2023				SUNDAY					
20.03.2023	MONDAY			ANNUAL DAY					
21.03.2023	TUESDAY		ANNUAL DAY						
22.03.2023	WEDNESDAY			GUDIPADVA					
23.03.2023	THURSDAY	PA-L PA 4.2 : Enumerate and describe mediators of acute inflammation.	CLINICAL POSTING	PH-P - 1.12, PE 14.3 (Batch A+B) Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal dysfunction	PA-P SGD (Batch B) PA 23.1 (II) Describe abnormal urinary findings in disease states and identify and describe common urinary abnormalities in clinical specimen PA 3.1 Describe the pathogenesis and pathology of Amyloidosis. PA 3.2 Identify and describe amyloidosis in a sathology specimen	MI-P SGD MI1.1 Identification of Bacteria (MOPRHOLOGY)+ Laboratory Diagnosis of viral infections			
24.03.2023	FRIDAY	MI-L MI1.4 Methods of sterilization		PH.L 1.4 Describe absorption, distribution, metabolism & excretion of drugs	CM-P (Batch B) CM 3.2 Visit to water filtration plant	FM- 2.29 , Skill in FMT- 14.22, Batch- A- SGD-2			
25.03.2023	SATURDAY	SUR-LBurns SU4.1 Elicit document and present history in a case of Burns and perform physical examination. Describe Pathophysiology of Burns. SU4.2 Describe Clinical features. Diagnose type and extent of burns andplan appropriate treatment. SU4.3 Discuss the Medicolegal aspects in burn injuries.	10-11 MI-L MI1.4 Disinfectants and CSSD 11-12 MED-L IM 4.7 Sepsis Syndrome 12-1 OBG-L OG 3.1 Physiology of gametogenesis, Ovulation, conception, implantation , & reproductive endocrinology	PA-L PA 4.3 Define and describe chronic inflammation including causes,types,nonspecific and granulomatous; and enumerate examples of each.	PH- P - 2.1 (Batch B) Demonstrate understanding of the use of various dosage forms	PA-P SGD (Batch A) PA 4.1 Define and describe the general features of acute and chronic inflammation including stimuli, vascular and cellular events.PA 4.2: Enumerate and describe mediators of acute inflammation. PA 4.4 identify and describe acute inflammation in gross and microscopic specimens			
26.03.2023				SUNDAY					
27.03.2023	MONDAY	PH-L - 1.5 Describe general principles of mechanism of drug action	CLINICAL POSTING	FM-1.8 & 1.9, Lecture-3 Legal procedure	PH- P - 2.1 (Batch A) Demonstrate understanding of the use of various dosage forms	PA-P SGD (Batch B) PA 4.1 Define and describe the general features of acute and chronic inflammation including stimuli, vascular and cellular events.PA 4.2: Enumerate and describe mediators of acute inflammation. PA 4.4 lentify and describe acute inflammation in gross and microscopic specimens			

28.03.2023	TUESDAY	PH-L - 1.6 Describe principles of Pharmacovigilance& ADR reporting systems		CM-L CM 3.2 Water II- Water purification processes & water quality standards	CM-P (Batch A) Visit to sewage treatment plant	FM- 2.29 Skill in FMT14.22 SGD -2 Batch -B
29.03.2023	WEDNESDAY	PA-L PA 5.1 Define and describe the process of repair and regeneration including wound healing and its types.		MI-P MI1.5 OSPE Choose appropriate method of sterilization and disinfection to be used in specific situations in the Laboratory.	PA-P SGD (Batch A) PA 4.3 Define and describe chronic inflammation including causes,types,nonspecific and granulomatous; and enumerate examples of each, PA 4.4 Identify and describe chronic inflammation in gross and microscopic specimens	MI-P SGD MI1.2 Gram Staining 1/Stool / Lab. Diagnosis of Parasitic Infection (DOAP)
30.03.2023	THURSDAY			RAMNAVAMI		
31.03.2023	FRIDAY	MI-L MI1.6 Mechanism of drug resistance, (Bacter	CLINICAL POSTING	PH-L - 1.7 + 1.8 1.7 Define, identify and describe the management of adverse drug reactions (ADR) 1.8 Identify and describe the management of drug interactions	CM-P (Batch B) Visit to sewage treatment plant	FM-3.1 SGD-3 Batch -A- Identifaction of Age determination
				April-2023		
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00
01.04.2023	SATURDAY	SUR-LBasic surgical skills SUI4.1 Describe Aseptic techniques, sterilization and disinfection. SUI4.2 Describe Surgical approaches, incisions and the use of appropriate instruments in Surgery in general. SUI4.3 Describe the materials and methods used for surgical wound closure and anastomosis (sutures, knots and needles)	10-11 MI-L Integration MI1.6 Antibiotic Policy/Antibiotics stewardship/AST, MIC, MBC (Pharmacology) 11-12 MED-L IM 4.8; 4.16; 4.18 FUO - Fever of Unknown Origin 12-1 OBG-L OG 4.1 Early development of embryo and fetus, development of Placenta, amniotic fluid, cord	, PA-L PA 13.1: Describe hematopolesis and extramedullary hematopolesis. PA 13.2 Describe the role of anticoagulants in hematology.	PH-P - 2.1 (Batch B) Demonstrate understanding of the use of various dosage forms	PA-P SGD (Batch A) PA 13.1 : Describe hematopolesis and extramedullary hematopolesis. PA 13.2 Describe the role of anticoagulants in hematology.
02.04.2023				SUNDAY		
03.04.2023	MONDAY	PH-L 1.64 Describe overview of drug development, Phases of clinical trials and Good Clinical Practice	CLINICAL POSTING	FM-LFM 3.1- Lecture -4 Define and describe Corpus Delicti, establishment of identity of living persons including race, Sex, religion, complexion, stature, age determination using morphology, teeth-eruption, decay, bite marks, bones-ossification centres, medico-legal aspects of age-Define and describe Corpus Delicti, establishment of identity of living persons including race, Sex, religion, complexion, stature, age determination using morphology, teeth-eruption, decay, bite marks, bones-ossification centres, medico-legal aspects of age, part i	PH-P - 2.1 (Batch A) Demonstrate understanding of the use of various dosage forms	PA-P SGD (Batch B) PA 13.1 : Describe hematopoiesis and extramedullary hematopoiesis. PA 13.2 Describe the role of anticoagulants in hematology.
04.04.2023	TUESDAY			MAHAVIRJAYANTI		
05.04.2023	WEDNESDAY	PA-L PA 13.3 : Define and classify anemia. PA 13.4 : Enumerate and describe the investigation of anemia	CLINICAL POSTING	MI-P Integration MI1.3 Epidemiology of infection diseases (PSM)	PA-P SGD (Batch A) PA 13.3 : Define and classify anemia. PA 13.4 : Enumerate and describe the investigation of anemia PA 13.5 Perform, identify and describe peripheral blood picture in anemia. Preparation of peripheral smear and perform differential expectations of peripheral smear and perform differential	MI-P SGD Lab diagnosis of Viral Infections (SGD)/ Gram Staining 2 (DOAP)

06.04.2023	THURSDAY	PA-L PA 14.1 Describe Iron metabolism. PA 14.2: Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia.		PH-SGD - 1.4Describe absorption, distribution, metabolism & excretion of drugs	PA-P SGD (Batch B) PA 13.3 : Define and classify anemia. PA 13.4 : Enumerate and describe the investigation of anemia. PA 13.5 Perform, identify and describe peripheral blood picture in anemia. Preparation of peripheral smear and perform differential leucocyte count, interpretation of peripheral	MI-P SGD Lab diagnosis of Viral Infections (SGD)/ Gram Staining 2 (DOAP)	
07.04.2023	FRIDAY	GOODFRIDAY					
08.04.2023	SATURDAY	SUR-LPre-op assessment, GA, SA, LA, pert-operative management SU11.1 Describe principles of Preoperative assessment. SU11.2 Enumerate the principles of general, regional, and local Anaesthesia. SU 10.1 Describe the principles of perioperative management of common surgical procedures	10-11 MI-L Integration MI1.8 Immunity (Paediatrics) 11-12 MED-L IM 25.1; 25.2; 25.3, 25.7; 25.8, Zoonotic Diseases, (Leptospirosis & Dengue) 12-1 OBG-L OG 2.1 Embryology and developmental defects of female genital tract	PA-L PA 15.1 Describe the metabolism of Vitamin B 12 and the etiology and pathogenesis of B12 deficiency. PA 15.2: Describe laboratory investigatins of macrocytic anemia. PA 15.4: Enumerate the differences and describe the etiology and distinguishing features of megaloblastic and nonmegaloblastic macrocytic anemia	PH- P - 2.1 (Batch B) Demonstrate understanding of the use of various dosage forms	PA-P SGD (Batch A) PA 14.1 Describe Iron metabolism. PA 14.2: Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia. PA 14.3 Identify and describe peripheral smear in microcytic anemia. Case based learning and interpretation of charts of Microcytic anemia Complete blood count Interpretation of report (without flags) from automated cell counter	
09.04.2023							
09.04.2023				SUNDAY			
10.04.2023	MONDAY	PH-L 1.14 Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs	CLINICAL POSTING	FM-3.2 Lecture-5 - Define and describe Corpus Delicti, establishment of identity of living persons including race, Sex, religion, complexion, stature, age determination using morphology, teeth-eruption, decay, bite marks, bones-ossification centres, medico-legal aspects of age, part II	PH- P.2.1 (Batch A) Demonstrate understanding of the use of various dosage forms	PA-P SGD (Batch B) PA 14.1 Describe Iron metabolism. PA 14.2 : Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia . PA 14.3 Identify and describe peripheral smear in microcytic anemia. Case based learning and interpretation of charts of Microcytic anemia Complete blood count Interpretation of report (without flags) from automated cell counter	
11.04.2023	TUESDAY	PH-L 1.14 Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs		CM-L CM 3.5 Standards of housing & the effect of housing on health	CM-P SDL (Batch A) CM 3.1, 3.2 Seminar in gruops of 10 on air pollution, water pollution, noise pollution, radiation hazards, medical entomology	FM-P Fm:3.18.14.4 (Batch B) Identification-age determination	
12.04.2023	WEDNESDAY	PAL PA 16.1: Define and classify Hemolytic anemia. PA 16.2: Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia. PA 16.3: Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia		MI-P Integration MI1.7 Structure & Functions of Immune System (Paediatrics)	PA-P SGD (Batch A) PA 15.1 Describe the metabolism of Vitamin B 12 and the etiology and pathogenesis of B12 deficiency, PA 15.2: Describe laboratory investigatins of macrocytic anemia.PA 15.3 Identify and describe peripheral smear in Macrocytic anemia PA 15.4: Enumerate the differences and describe the etiology and distinguishing features of megaloblastic and nonmegaloblastic macrocytic anemia. Case based learning and interpretation of charts of Macrocytic anemia. Interpretation of report of	MI-P SGD Lab diagnosis of Fungal Infections/ Gram Staining 3 (DOAP)	
13.04.2023	THURSDAY	PAL PA 16.4 Describe the etiology, pathogenesis,hematologic indices and peripheral blood picture of Acquired Hemolytic Anemia. PA 16.5: Describe the peripheral blood picture in different hemolytic anaemias. PA 16.7: Describe the correct technique to perform a cross match		PH-T - 1.5 Describe general principles of mechanism of drug action	PA-P SGD (Batch B) PA 15.1 Describe the metabolism of Vitamin B 12 and the etiology and pathogenesis of B12 deficiency. PA 15.2: Describe laboratory investigatins of macrocytic anemia.PA 15.3 Identify and describe peripheral smear in Macrocytic anemia PA 15.4: Enumerate the differences and describe the etiology and distinguishing features of megaloblastic and nonmegaloblastic macrocytic anemia Case based learning and interpretation of charts of Macrocytic anemia. Interpretation of report of	MI-P SGD Lab diagnosis of Fungal Infections/ Gram Staining 3 (DOAP)	
14.04.2023	FRIDAY			DR AMBEDKAR JAYANTI			
15.04.2023	SATURDAY	SUR-LPrinciple of Gen, Surgery and pain management SU11.4 Enumerate the indications and principles of day care GeneralSurgery, SU11.5 Describe principles of providing post-operative pain relief and management of chronic pain. SU11.6 Describe Principles of safe General Surgery	10-11 MI-LAntibodies MI1.8	PA-L PA 17.1: Enumerate the etiology, pathogenesis and findings in Aplastic anemia. PA 17.2: Enumerate the indications and describe the findings in bone marrow aspiration and biopsy	PH- P (Batch B) P 3.4 Adverse drug reaction- identification and reporting	PA-P SGD (Batch A) PA 16.1 : Define and classify Hemolytic anemia. PA 16.2 : Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia. PA 16.3 : Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia. Case based learning and interpretation of charts of Haemolytic anemia	

I	1		W WIND I			naemoiyuc anemia
			11-12 MED-L IM 25.1; 25.2; 25.3,, 25.7,25.8, Rabies & Tetanus 12-1 OBG-L OG 6.1 Diagnosis of pregnancy			
16.04.2023				SUNDAY		
17.04.2023	MONDAY	PH-L - 1.13 Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs	CLINICAL POSTING	FM-3.2 Lecture 6 Describe and discuss identification of criminals, unknown persons, dead bodies from the remains-hairs, fibers, teeth, anthropometry, dactylography, foot prints, scars, tattoos, poroscopy and superimposition	PH- P (Batch A) P 3.4 Adverse drug reaction- identification and reporting	PA-P SGD (Batch B) PA 16.1: Define and classify Hemolytic anemia. PA 16.2: Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia. PA 16.3: Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia. Case based learning and interpretation of charts of Haemolytic anemia
18.04.2023	TUESDAY	PH-L - 1.13 Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs		CM-L CM 7.2 Modes of transmission & meausres for prevention & control of Communicable diseases	CM-P (Batch A) Visit to office of District Vector-borne Disease Control programme	FM- 2.11,2,12,2.13,2.14 SGD-5 (batch B) Describe and dispescribe the legal requirements to conduct post-mortem examination and procedures to conduct medico-legal post Describe and discuss obscure autopsy Describe and discuss examination of clothing, preservations of the control of the cont
19.04.2023	WEDNESDAY	PA-L PA 18.1 : Enumerate and describe the causes of leucocytosis, leucopenia, lymphocytosis and leukemoid reactions		MI-P MI1.8 Antigen ,Complement	PA-P SGD (Batch A)PA 16.4: Describe the etiology, pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic Anemia PA 16.5: Describe the peripheral blood picture in different hemolytic anaemias PA 16.6: Perpare a peripheral blood smear and identify haemolytic anemia from it. PA 16.7: Describe the correct technique to perform a cross match Case based learning and interpretation of charts of Haemolytic anemia. Haematocrit and Erythrocyte	MI-P SGDMI1.2 ZN staining-1 (DOAP) /Culture media Revision
20.04.2023	THURSDAY	PA-L PA 18.2 : Describe the etiology, genetics, pathogenesis, classification, hematologic features of acute and chronic leukemia		PH-P (Batch A+B) P 3.4 Adverse drug reaction- identification and reporting	PA-P SGD (Batch B)PA 16.4: Describe the etiology, pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic Anemia PA 16.5: Describe the peripheral blood picture in different hemolytic anaemias PA 16.6: Prepare a peripheral blood smear and identify haemolytic anemia from it. PA 16.7: Describe the correct technique to perform a cross match Case based learning and interpretation of charts of Haemolytic anemia Haematocrift and Erythrocyte	MI-P SGD MI1.2 ZN staining-1 (DOAP) /Culture media Revision
21.04.2023	FRIDAY	MI-LMI1.8 Immune response		PH-L - 1.13 Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti- adrenergic drugs	CM-P (Batch B) Visit to office of District Vector-borne Disease Control programme	FM 2.11. 12. 13, 14,15,16,17,18 - SGD- 6 (batch ADescribe and discuss autopsy procedures including post-mortem examination, different types of autopsies, aims and objectives of post-mortem examination Describe the legal requirements to conduct post-mortem examination and procedures to conduct medico-legal post-mortem examination Describe and discuss obscure autopsy
22.04.2023	SATURDAY			RAMZAN-EID		
23.04.2023				SUNDAY		
24.04.2023	MONDAY	PH-L -1.16 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminic, 5-HT modulating drugs, NSAIDs, drugsfor gout, anti rheumaticdrugs, drugs for migraine	CLINICAL POSTING	FM- 2.1.2.83 -Lecture-7 Define, describe and discuss death and its types including somatic/linical/cellular, molecular and brain-death, Cortical Death and Brainstem Death Describe and discuss natural and unnatural deaths Describe and discuss issues related to sudden natural deaths	PH- P (Batch A) P 3.4 Adverse drug reaction- identification and reporting	FM-2.15, 16,17 &18-SGD-6(batch B) Describe special protocols for conduction of medico-legal autopsies in cases of death in custody or following violation of human rights as per National Human Rights Commission Guidelines. Describe and discuss examination of mutilated bodies or fragments, charred bones and bundle of bones. Describe and discuss exhumation.

25.04.2023	TUESDAY	PH-L -1.16 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminic, 5-HT modulating drugs, NSAIDs, drugsfor gout, anti rheumaticdrugs, drugs for migraine		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Arthropod borne diseases: Malaria	CM-P (Batch A) CM 3.7 Demonstration: Identifying characteristics of vectors of public health importance	
26.04.2023	WEDNESDAY	PA-L PA 19.1 Enumerate the causes and describe the differentiating features of lymphadenopathy. PA 19.2 Describe the pathogenesis and pathology of tuberculous lymphadenitis		MI-P Integration MI1.10 Hypersensitivity I (Paediatrics)(Patholo	PA-P SGD (Batch A) PA 18.1: Enumerate and describe the causes of leucocytosis, leucopenia, lymphocytosis and leukemoid reactions .PA 18.2: Describe the etiology, genetics, pathogenesis, classification, hematologic features of acute and chronic leukemia. Interpretation of charts of acute and chronic leukaemia	MI-P SGDMI1.2 ZN staining-2 (DOAP) / MI11.9 Vaccines demonstration
27.04.2023	THURSDAY	PA-L PA 19.4 Describe and discuss the pathogenesis,pathology and the differentiating features of Hodgkin's and Non-Hodgkin's lymphoma PA 19.6 Enumerate and differentiate the causes of splenomegaly		PH-P (Batch A+B) P 3.4 Adverse drug reaction- identification and reporting	PA-P SCD (Batch B) PA 18.1 : Enumerate and describe the causes of leucocytosis, leucopenia, lymphocytosis and leukemoid reactions .PA 18.2 : Describe the etiology, genetics, pathogenesis, classification, hematologic features of acute and chronic leukemia. Interpretation of charts of acute and chronic leukemia	MI-P SGD MI1.2 ZN staining-2 (DOAP) / MI11.9 Vaccines demonstration
28.04.2023	FRIDAY	MI-L Integration MI1.10 Hypersensitivity II (Paediatrics)(Pathology)		PHL -1.16 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminic, 5-HT modulating drugs, NSAIDs, drugsfor gout, anti rheumaticdrugs, drugs for migraine	CM-P (Batch B) CM 3.7 Demonstration: Identifying characteristics of vectors of public health importance	FM-1.10 & 11 SGD-7 (Batch A) Select appropriate cause of death in a particular scenario by referring ICD 10 code Write a correct cause of death certificate as per ICD 10 document
29.04.2023	SATURDAY	SUR-LFluid therapy in surgical patient SU12,2 Describe and discuss the methods of estimation and replacement of the fluid and electrolyte requirements in the surgical patient.	10-11 MI-L MI1.8 Antigen Antibody Reactions I 11-12 MED-L IM 25.1; 25.2; 25.3, 25.7; 25.8, Scrub Typhus, Typhoid	PA-L PA 21.1 Describe normal hemostasis. PA21.2 Classify and describe the etiology, pathogenesis and pathology of vascular and platelet disordersincluding ITP and haemophilias.	PH- P (Batch B) P 3.4 Adverse drug reaction- identification and reporting	PA-P SGD (Batch A)PA 19.1 Enumerate the causes and describe the differentiating features of lymphadenopathy. PA 19.2 Describe the pathogenesis and pathology of tuberculous lymphadenitis. PA 19.3 Identify and describe the features of tuberculous lymphadenitis in gross and microscopic specimen PA 19.4 Describe and discuss the pathogenesis, pathology and the differentiating features of Hodgkin's and Non-Hodgkin's lymphoma PA 19.5 Identify and describe the features of Hodgkins lymphoma in a gross and microscopic specimen
30.04.2023				SUNDAY		
				May-2023		
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00
01.05.2023	MONDAY			MAHARSHTRA DIN		
02.05.2023	TUESDAY	PH-L -1.16 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminic, 5-HT modulating drugs, NSAIDs, drugsfor gout, anti-rheumaticdrugs, drugs for migraine	CLINICAL POSTING	CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Arthropod borne diseases: Dengue	CM-P (Batch A) 8.1 Visit to District office related to implementation of Disease Control Measures of Communicable diseases: Visit to Public Health Laboratory	FM-1.10 &11-SGD-7 Batch- B Select appropriate cause of death in a particular scenario by referring ICD 10 code Write a correct cause of death certificate as per ICD 10 document

03.05.2023	WEDNESDAY	PA-L PA 21.3 Differentiate platelet from clotting disorders based on clinical and hematologic features. PA 21.4 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of disseminated intravascular coagulation. PA 21.5 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of Vitamin K deficiency.		MI-P MI1.8 Antigen Antibody Reactions II	PA-P SGD (Batch A)PA 19.6 Enumerate and differentiate the causes of splenomegaly. PA 19.7 Identify and describe the gross specimen of an enlarged spleen. PA 20.1 Describe the features of plasma cell myeloma. Case based learning and interpretation of charts of Multiple Myeloma	MI-P SGDM 1.2 ZN staining-3 (DOAP)
04.05.2023	THURSDAY	PA-L PA 22.1 Classify and describe blood group systems (ABO and Rh). Pa 22.2 Enumerate the indications,describe the principles,enumerate and demonstrate the steps of compatibility testing PA 22.4 Enumerate blood components and describe their clinical uses.		P -4.2 Demonstrate the effects of drugs on blood pressure using computer aided learning (Drugs on BP (CAL)	PA-P SGD (Batch B)PA 19.6 Enumerate and differentiate the causes of splenomegaly. PA 19.7 Identify and describe the gross specimen of an enlarged spleen. PA 20.1 Describe the features of plasma cell myeloma. Case based learning and interpretation of charts of Multiple Myeloma.	MI-P SGDMI1.2 ZN staining-3 (DOAP)
05.05.2023	FRIDAY			BUDDHA PURNIMA		
06.05.2023	SATURDAY	SUR-LNutrition in surgical patient SU12.1 Enumerate the causes and consequences of malnutrition in the surgical patient SU12.3 Discuss the nutritional requirements of surgical patients, themethods of providing nutritional support and their complications	MI-P Integration MI1.9 Vaccines, universal vaccination program, Immunoprophylaxis, Immunotherapy (Paediatrics) 11-12 MED-L IM 25.1; 25.2;, 25.3, 25.7, 25.8, Acute encephalitis syndromes including JE	PA-L PA 22.5 Enumerate and describe infections transmitted by blood transfusion. PA 22.6 Describe tranfusion reactions and enumerate the steps in the investigation of transfusion reaction. PA 22.7 Enumerate the indications and describe the principles and procedure of autologous transfusion	PH- P-(Batch B) 4.2 Demonstrate the effects of drugs on blood pressure using computer aided learning (Drugs on BP (CAL)	PA-P SGD (Batch A)Revision + missed slides
07.05.2023				SUNDAY		
08.05.2023	MONDAY			SUMMER VACATION		
09.05.2023	TUESDAY			SUMMER VACATION		
10.05.2023	WEDNESDAY			SUMMER VACATION		
11.05.2023	THURSDAY			SUMMER VACATION		
12.05.2023	FRIDAY			SUMMER VACATION		
13.05.2023	SATURDAY			SUMMER VACATION		
14.05.2023				SUNDAY		
15.05.2023	MONDAY			SUMMER VACATION		
16.05.2023	TUESDAY			SUMMER VACATION		
17.05.2023	WEDNESDAY			SUMMER VACATION		
18.05.2023	THURSDAY			SUMMER VACATION		
19.05.2023	FRIDAY			SUMMER VACATION		
20.05.2023	SATURDAY			SUMMER VACATION		
21.05.2023				SUNDAY		
22.05.2023	MONDAY	PH-L -1.15 PY-3.5-AS-4.1 Describe mechanism / s of action, types, doses, side effects, indications and contra-indications of skeletal muscle relaxants	CLINICAL POSTING	FM2.5, 6, 7, & 8 Lecture 8 Discuss moment of death, modes of death - coma, asphyxia and syncope Discuss presumption of death and survivorship Describe and discuss suspended animation Describe and discuss postmortem changes including signs of death, cooling of body, post-mortem lividity, rigor mortis, cadaveric spasm, cold stiffening and heat stiffening	PH-P(Batch A) 1.10 Describe parts of a correct, Complete and legible generic prescription. Identify errors in prescription and correct appropriately	PA-P SGD (Batch B)PA 21.1 Describe normal hemostasis. PA21.2 Classify and describe the etiology, pathogenesis and pathology of vascular and platelet disordersincluding ITP and haemophilias. PA 21.3 Differentiate platelet from clotting disorders based on clinical and hematologic features. Interpretation of charts of bleeding and clotting disorder.

23.05.2023	TUESDAY	PH-L 1.17 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local anesthetics		CM-L 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Arthropod borne diseases: Filaria, JE, Chickungunya, Kala Azar	CM-P (Batch A) Journal & logbook correction/ Formative assessment	FM1.10 & 11 SGD -7 (batch B) Select appropriate cause of death in a particular scenario by referring ICD 10 code Write a correct cause of death certificate as per ICD 10 document
24.05.2023	WEDNESDAY	PA- SDL PA 22.1 Classify and describe blood group systems (ABO and Rh.) Pa 22.2 Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing PA 22.4 Enumerate blood components and describe their clinical uses.PA 22.5 Enumerate and describe infections transmitted by blood transfusion. PA 22.6 Describe tranfusion reactions and enumerate the steps in the investigation of transfusion reaction. PA 22.7 Enumerate the indications and describe the principles and procedure of autologous transfusion		MI-P Integration MI1.10/11Autoimmune disorder,immunodeficiency,immunological mechanism of tumor immunity	PA-P SGD (Batch A)PA 21.4 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of disseminated intravascular coagulation. PA 21.5 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of Vitamin K deficiency. Interpretation of charts of bleeding and clotting disorder.	MI-P SGDMI1.8 Serological reactions
25.05.2023	THURSDAY	PA-L PA 6.1 : Define and describe edema its types,pathogenesis and clinical correlation. PA 6.2 Define and describe hyperemia, congestion , hemorrhage		PH-P-3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	PA-P SGD (Batch B)PA 21.4 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of disseminated intravascular coagulation, PA 21.5 Define and describe disseminated intravascular coagulation, its laboratory findings and diagnosis of Vitamin K deficiency Interpretation of charts of bleeding	MI-P SGDMI1.8 Serological reactions
26.05.2023	FRIDAY	MI-L Integration MI2.4 Anemia Hookworm, Trichuri (General Medicine) (Pathology)		PHL -1.24 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs affecting renal systems including diuretics, antidiuretics-vasopressin and analogues	CM-P (Batch A) CM 8.1 Visit to District office related to implementation of Disease Control Measures of Communicable diseases : Visit to Immunization Clinic	FM 2.33. 34. 35-SGD-8-(Batch B) Demonstrate ability to use local resources whenever required like in mass disaster situations Demonstrate ability to use local resources whenever required like in mass disaster situations Demonstrate professionalism while conducting autopsy in medicolegal situations, interpretation of findings and making inference/opinion, collection preservation and dispatch of hiological or trace evidences
27.05.2023	SATURDAY	SUR-LBlood and blood component SU3.1 Describe the Indications and appropriate use of blood and blood products and complications of blood transfusion.	10/11/2023 Integration MI2.5, Malaria, Babesiosis (General Medicine) (Pathology)	PA-L PA 6.3 Define and describe shock, its pathogenesis and its stages. PA 6.4 Define and describe normal haemostasis and the etiopathogenesis and consequences of thrombosis	PH- P (Batch B) 1.10 Describe parts of a correct, Complete and legible generic prescription. Identify errors in prescription and correct appropriately	PA-P SGD (Batch A)PA 21.1 Describe normal hemostasis. PA21.2 Classify and describe the etiology, pathogenesis and pathology of vascular and platelet disordersincluding ITP and haemophilias. PA 21.3 Differentiate platelet from clotting disorders based on clinical and hematologic features Interpretation of charts of bleeding and clotting disorder.
			11-12 MED-L IM 5.1 to 6.3 symptoms and signs of acute HIV , classify HIV AIDS			
			12-1 OBG-L OG- 5.1, 5.2 And 75.5 Preconceptional counseling			
28.05.2023				SUNDAY		
29.05.2023	MONDAY	PH-L L1.26 Describe mechanisms of action, types, doses, side effects, indications and contraindications of the drugs modulating the renin- angiotensin and aldosterone system	CLINICAL POSTING	FM-2,9 lecture 9 Describe putrefaction, mummification, adipocere and maceration	PH-P-(Batch A) 2.3 lv drip setting	PA-P SGD (Batch B)PA 22.1 Classify and describe blood group systems (ABO and Rh). Pa 22.2 Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing PA 22.4 Enumerate blood components and describe their clinical uses.
30.05.2023	TUESDAY	PH-L -1.27 IM-8.14 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of antihypertensive drugs and drugs used in shock		CM-L CM 3.6, 8.3 Disease specific National Health Programs including their prevention and treatment of a case: NVBDCP	CM-P (Batch B) CM 8.1 Visit to District office related to implementation of Disease Control Measures of Communicable diseases : Visit to Immunization Clinic	FM 2.33, 34 &5 -SGD-8 (Batch A) Demonstrate ability to use local resources whenever required like in mass disaster situations Demonstrate ability to use local resources whenever required like in mass disaster situations Demonstrate professionalism while conducting autopsy in medicolegal situations, interpretation of findings and making inference/opinion, collection preservation and dispatch of biological or trace evidences
31.05.2023	WEDNESDAY	PA-L PA 6.5 Define and describe embolism and its causes and common types. PA 6.6 Define and describe ischaemia/infarction, its types, etiology, morphologic changes and clinical effects.		MI-P Integration MI2.5 Kala azar, Trypanosoma (General Medicine) (Pathology)	PA-P SGD (Batch A)PA 22.5 Enumerate and describe infections transmitted by blood transfusion. PA 22.6 Describe tranfusion reactions and enumerate the steps in the investigation of transfusion reaction. PA 22.7 Enumerate the indications and describe the principles and procedure of autologous transfusion.Perform blood group and	MI-P SGD Formative assessement - General Bacteriology & Immunology

				June-2023		
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00
01.06.2023	THURSDAY	PA-L PA 9.1 Describe the principles and mechanisms involved in immunity. PA 9.2 Describe the mechanism of hypersensitivity reactions	CLINICAL POSTING	PH-P-1.14 SDL-1 Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs	PA-P SGD (Batch B) PA 22.5 Enumerate and describe infections transmitted by blood transfusion. PA 22.6 Describe tranfusion reactions and enumerate the steps in the investigation of transfusion reaction. PA 22.7 Enumerate the indications and describe the principles and procedure of autologous transfusion.Perform blood group and	MI-P SGD Formative assessement - General Bacteriology & Immunology
02.06.2023	FRIDAY	MI-LIntegration MI2.5 Filariasis (General Medicine) (Pathology)		PH-L -1.27 IM-8.14 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of antihypertensive drugs and drugs used in shock	CM-P (Batch A) CM 8.1 Visit to District office related to implementation of Disease Control Measures of Communicable diseases: Visit to District TB Office	FM14.9 SGD-9 (Batch B) Demonstrate examination of & present an opinion after examination of skeletal remains in a simulated/ supervised environment
03.06.2023	SATURDAY	SUR-Linvestigations in surgical patient SU 9.1 Choose appropriate biochemical, microbiological, pathological, imaging investigations and interpret the investigative data in asurgical patient SU9.2 Biological basis for early detection of cancer and multidisciplinary approach in management	10-11 MI-LIntegration MI2.5 Other common parasites prevalent in India - Schistosomes, (General Medicine) (Pathology) 11-12 MED-L	PA-L PA 9.3 Describe the HLA system and the immune principles involved in transplant and mechanism of transplant rejection. PA 9.4 Define autoimmunity .Enumerate autoimmune disorders	PH- P-(Batch -B) 2.3 lv drip setting	PA-P SGD (Batch A) PA 22.1 Classify and describe blood group systems (ABO and Rh). Pa 22.2 Enumerate the indications, describe the principles, enumerate and demonstrate the steps of compatibility testing PA 22.4 Enumerate blood components and describe their clinical uses.
			IM 6.4 to 6.6; 6.9 opportunistic infections, malignancies, skin and oral lesions, malignancies, skin and oral lesions,			
			12-1 OBG-L OG 8.1, 8.2(K), 8.3(K) Antenatal Care, birth planning, and Obstetric examination			
04.06.2023				SUNDAY		
05.06.2023	MONDAY	PH-L 1.28 IM-2.15 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in ischemic heart disease (stable, unstable angina and myocardial infarction), peripheral vascular disease	CLINICAL POSTING	FM 2.30 SDL-2 Have knowledge/awareness of latest decisions/notifications/ resolutions/circulars/standing orders related to medico-legal practice issued by Courts/Government authorities etc	PH- P -(Batch A) 3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	PA-P SGD (Batch B) PA 6.1: Define and describe edema lits types, pathogenesis and clinical correlation. PA 6.2 Define and describe hyperemia, congestion, hemorrhagePA 6.3 Define and describe shock, its pathogenesis and its stages. PA 6.4 Define and describe normal haemostasis and the etiopathogenesis and consequences of thrombosis
06.06.2023	TUESDAY	PH-L -1.29 IM-1.24 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Airborne infections: Tuberculosis	CM-P (Batch B) CM 8.1 Visit to District office related to implementation of Disease Control Measures of Communicable diseases : Visit to District TB Office	FM14.9 SGD- 9 (Batch A) Demonstrate examination of & present an opinion after examination of skeletal remains in a simulated/ supervised environment
07.06.2023	WEDNESDAY	PA-L PA 9.5 Define and describe the pathogenesis of Systemic Lupus Erythematosus. PA 9.7 Define and describe the pathogenesis of other common autoimmune diseases.		MI-PMI1.1, 2.4, 8.15 Blood stream infections - rheumatic fever-streptococcus pyogens/Bacterial enocarditis/	PA-P SGD (Batch A) PA 6.5 Define and describe embolism and its causes and common types. PA 6.6 Define and describe ischaemia/infarction,its types,etiology, morphologic changes and clinical effects. PA 6.7 Identify and describe the gross and microscopic features of infarction in a pathologic specimen	MI-P SGDIaboratory identification of microbial agents causing anaemia MI2.4

08.06.2023	THURSDAY	PA-L PA 9.6 Define and describe the pathogenesis and pathology of HIV and AIDS		PH-P- 1.14 SDL-1 Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs	PA-P SGD (Batch B) PA 6.5 Define and describe embolism and its causes and common types. PA 6.6 Define and describe ischaemia/infarction,its types,etiology, morphologic changes and clinical effects. PA 6.7 Identify and describe the gross and microscopic features of infarction in a pathologic specimen	MI-P SGD laboratory identification of microbial agents causing anaemia MI2.4
20.00.000	FRIDAY	MI-LMI-L Integration MI2.7 HIV (General Medicine) (Pathology)		PHL -1.29 IM-1.24 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure	CM-P (Batch A) CM 8.1 Visit to District office related to implementation of Disease Control Measures of Communicable diseases : Visit to ART Centre	FM14.4 Practical(SGD-10(Batch B) Conduct and prepare report of estimation of age of a person for medico-legal and other purposes & prepare medico-legal report in a simulated/ supervised environment
09.06.2023						
10.06.2023	SATURDAY	SUR-LSurgical Infections SU 6.1Define and describe the aetiology and pathogenesis of surgicalInfections SU6,2 Enumerate Prophylactic and therapeutic antibioticsPlan appropriate	10-11 MI-L Viral hemorrhagic fever	PA-L PA 11.1 Describe the pathogenesis and features of common cytogenetic abnormalities and mutations in childhood. PA 11.2 Describe the pathogenesis and pathology of tumour and tumour like conditions in infancy and childhood. PA11.3. Describe the pathogenesis of common storage disorders in infancy and childhood	PH- P -(Batch B) 3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	PA-P SGD (Batch A) PA 6.1: Define and describe edema its types, pathogenesis and clinical correlation. PA 6.2 Define and describe hyperemia, congestion, hemorrhagePA 6.3 Define and describe shock, its pathogenesis and its stages. PA 6.4 Define and describe normal haemostasis
			11-12 MED-L IM 6.16 to 6.18 HAART, post exposure prophylaxis , drugs used to prevent HIV related opportunistic infections 12-1 OBG-L-OG 8.4, 16.3-Antenatal screening, genetic counselling and			
			antenatal monitoring of fetal well being			
11.06.2023				SUNDAY		
	MONDAY	PH-L -1.30 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of the antiarrhythmics	CLINICAL POSTING	FM2.10 Lecture- 10 - Discuss estimation of time since death	PH- P (Batch A) -4.2 Demonstrate the effects of drugs on blood pressure using computer aided learning (Drugs on BP (CAL)	PA-P SGD (Batch B) SGD PA 19.1 Enumerate the causes and describe the differentiating features of lymphadenopathy. PA 19.2 Describe the pathogenesis and pathology of tuberculous lymphadenitis. PA 19.3 Identify and describe the features of tuberculous lymphadenitis in gross and microscopic specimen PA 19.4 Describe and discuss the pathogenesis, pathology and the differentiating features of Hodgkin's and Non-Hodgkin's lymphoma PA 19.5 Identify and describe the features of Hodgkin gross and
12.06.2023						microscopic specimen
	WEDNESDAY	PA- SDL PA 11.1 Describe the pathogenesis and features of common cytogenetic abnormalities and mutations in childhood. PA 11.2 Describe the pathogenesis and pathology of tumour and tumour like conditions in infancy and childhood. PA11.3. Describe the pathogenesis of common storage disorders in infancy and		MI-PMI1.1 MI .15 Rickettsial Infections Weil Felix Test	PA-P SGD (Batch A): REVISION PRACTICAL	MI-P SGDMI2.6 Peripheral smear staining /Case discussion Diagnosis of malaria and filaria (General Medicine)
14.06.2023		childhood		THE CANE IS A SECOND OF THE CONTRACT OF THE CO		W. 7.007 W. 0.7
	THURSDAY	PA-L REVISION (BATCH A +B)		PH-P-3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	PA-P SGD (Batch B): REVISION PRACTICAL	MI-P SGD MI2.6 Peripheral smear staining /Case discussion Diagnosis of malaria and filaria (General Medicine)
15.06.2023						
16.06.2023	FRIDAY		I st INT	TERNAL ASSESSMENT EXAMINATION		
17.06.2023	SATURDAY		I st INT	ERNAL ASSESSMENT EXAMINATION		
18.06.2023				SUNDAY		
19.06.2023	MONDAY	I st INTERNAL ASSESSMENT EXAMINATION				
20.06.2023	THEOD AND	I st INTERNAL ASSESSMENT EXAMINATION				
20.00.2023	TUESDAY					
21.06.2023	WEDNESDAY			ERNAL ASSESSMENT EXAMINATION		
			I st INT			

25.06.2023				SUNDAY				
	SATURDAY							
24.06.2023 26.06.2023	MONDAY		I st INTERNAL ASSESSMENT EXAMINATION					
			I st INTERNAL ASSESSMENT EXAMINATION					
27.06.2023	TUESDAY		I st INTERNAL ASSESSMENT EXAMINATION					
28.06.2023	WEDNESDAY			BAKARI EID				
29.06.2023	THURSDAY		I st INT	ERNAL ASSESSMENT EXAMINATION				
30.06.2023	FRIDAY		I st INT	ERNAL ASSESSMENT EXAMINATION				
				July-2023				
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00		
01.07.2023	SATURDAY		PH-L -1.35 IM-9.15 Describe the mechanism's of action, types, doses, side effects, indications and contraindications of drugs used in hematological disorders like:1.Drugsused in anemias 2.CSF 11-12 MED-L IM 16.1; 16.13; 16.14; 16.6, IM 16.11; 16.12 acute and chronic diarrhea, diarrhea vs dysentery, Investigation for diagnosis of acute and chronic diarrheal diseases pharmacotherapy for parasitic, bacterial and viral causes of diarrhea 12-1 OBG-L OG 8.7 Vaccines and medications in pregnancy, Teratology	MI-Pintegration Mis.3 Enteric tever (General Medicine) (Pathology) (Pharmacology)	PH-L-1,25 IM-2.23 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets,	PA-L PA 7.1 Define and classify Neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and spread. Differentiate between benign from malignant neoplasms		
02.07.2023				SUNDAY				
03.07.2023	MONDAY	PA-L PA 7.2 Describe the molecular basis of cancer	CLINICAL POSTING	PA-P SGD (Batch A+B)PA 9.1 Describe the principles and mechanisms involved in immunity, PA 9.2 Describe the mechanism of hypersensitivity reactionsPA 9.3 Describe the HLA system and the immune principles involved in transplant and mechanism of transplant rejection. PA 9.4 Define autoimmunity. Enumerate autoimmune disordersPA 9.5 Define and describe the pathogenesis of Systemic Lupus Erythematosus. PA 9.7 Define and describe the pathogenesis of other common autoimmune diseases.PA 9.6 Define and describe the pathogenesis of other common autoimmune diseases.PA 9.6 Define and describe the pathogenesis and pathology of HIV and AIDS.	PH-P-(Batch A)2.4 Dosage calculation	PA-P SGD (Batch B) PA 7.1 Define and classify Neoplasia. Describe the characteristics of neoplasia including gross,microscopy, biologic, behaviour and spread. Differentiate between benign from malignant neoplasms		
04.07.2023	TUESDAY	PH-L 1.25 IM-2.23 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets,		PH-P T-1.28 IM-2.15 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in ischemic heart disease (stable, unstable angina and myocardial infarction), peripheral vascular disease	,	AETCOM		
05.07.2023	WEDNESDAY	PA-L PA 7.3 Enumerate carcinogens and describe the process of carcinogenesis		PH-SGD- 1.25 IM-2.23 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets,	PA-P SGD (Batch A)PA 7.2 Describe the molecular basis of cancer.PA 7.3 Enumerate carcinogens and describe the process of carcinogenesis	MI-P SGD stool Microscopy-I		

06.07.2023	THURSDAY	MI-LMI 8.1 Misc bloodstream infections Brucella, Leptosirosis, Borreliosis		FM 2.19 Lecture 11 Investigation of anaesthetic, operative deaths: Describe and discuss special protocols for conduction of autopsy and for collection, preservation and dispatch of related material evidences	PH-P-(Batch B)2.4 Dosage calculation	PA-P SGD (Batch A) PA 7.1 Define and classify Neoplasia. Describe the characteristics of neoplasia including gross, microscopy, biologic, behaviour and spread.Differentiate between benign from malignant neoplasms
07.07.2023	FRIDAY	MI-LIntegration MI3.1 Microbial agents causing diarrhea and dysentery-V cholera		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections and STDs: HIV	PA-P SGD (Batch B)PA 7.2 Describe the molecular basis of cancer.PA 7.3 Enumerate carcinogens and describe the process of carcinogenesis	MI-P SGDSGD stool Microscopy-I
08.07.2023	SATURDAY	SUR-LTrauma-II Chest injuries pathophysiology of chest injuries. SU17.9 Describe the clinical features and principles of management of chest injuries	PH-L 1.25 IM-2.23 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets,	MI-Pintegration MI3.1 Shigelia dysentery Campylobacter (General Medicine) (Paediatrics)	PA-L PA 7.4 Describe the effects of tumour on host including paraneoplastic syndromes .PA 7.5 Describe immunologyand the immune response to cancer	
			11-12 MED-L M 16.2; 16.3 acute systemic consequences of diarrhea, chronic effects of diarrhea			
			12-1 -OG 13.1-Labor physiology			
09.07.2023				SUNDAY		
10.07.2023	MONDAY	PA-L PA24.1 Describe the etiology, pathogenesis and clinical features of oral cancers. PA 24.2 Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease. PA24.3. Describe and identify the microscopic features of peptic ulcer	CLINICAL POSTING	PA- L PA24.4 Describe the etiology and pathogenesis and pathologic features of Carcinoma of the stomach. PA 24.5 Describe the etiology and pathogenesis and pathologic features of Tuberculosis of the intestine	PH-P-(Batch A) 3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	PA-P SGD (Batch B)PA24.1 Describe the etiology, pathogenesis and clinical features of oral cancers. PA 24.2 Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease. PA24.3. Describe and identify the microscopic features of peptic ulcer. PA24.4 Describe the etiology and pathogenesis and pathologic features of Carcinoma of the stomach.
11.07.2023	TUESDAY	PH-L -1.18 AS-4.1 Describe the mechanism/ s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and pre- anestheticmedications		PH-P 1.29 SDL-2 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure	,	AETCOM
12.07.2023	WEDNESDAY	PA-L PA 24.6 Describe the etiology and pathogenesis and pathologic and distinguishing featuresof inflammatory bowel disease. PA24.7: Describe the etiology, pathogenesis, pathology and distinguishing features of Carcinoma of the colon.		PH.P 1.29 SDL-2 Describe the mechanism s of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure	PA-P SGD (Batch A)PA 24.5 Describe the etiology and pathogenesis and pathologic features of Tuberculosis of the intestinePA 24.6 Describe the etiology and pathogenesis and pathologic and distinguishing features of inflammatory bowel disease. PA24.7: Describe the etiology, pathogenesis, pathology and distinguishing features of	MI-P SGD Stool M icroscopy-II/1 dentify the common bacterial etiologic agents of diarrhea /dysentery -vibrio/Shigella
13.07.2023	THURSDAY	MI-LMI3.1 Parasites causing, dysentery E. hystolytica		FM8.1 SDL-3 Describe the history of Toxicology	PH-P-(Batch - B)-3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	pathogenesis and clinical features of oral cancers. PA

14.07.2023	FRIDAY	MI-LMI3.1 Intestinal nematodes I		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Surface infections and STDs: STDs (Syphills, Gonorrhea etc)	PA-P SGD (Batch B)PA 24.5 Describe the etiology and pathogenesis and pathologic features of Tuberculosis of the intestinePA 24.6 Describe the etiology and pathogenesis and pathologic and distinguishing features of inflammatory bowel disease, PA24.7: Describe the etiology, pathogenesis, pathology and distinguishing features of	MI-P GD Stool M icroscopy-ll/I dentify the common bacterial etiologic agents of diarrhea /dysentery -vibrio/Shigella
15.07.2023	SATURDAY	SUR-LTrauma-III Head injuries SU17.4 Describe Pathophysiology, mechanism of head injuries SU17.5 Describe clinical features for neurological assessment and GCS in head injuries SU17.6 Chose appropriate investigations and discuss the principles ofmanagement of head injuries	neurodegenerative disorders, anti-epileptics drugs) 11-12 MED-L IM 16.15-16.17 Crohn's disease, Ulcerative Colitis, inflammatory bowel disease	MI-PMI3.1. Giardia, B. coli, H. Nana and intestinal trematodes	MI-LIMI3.1 Taenia , other cestodes	PA- L PA25.1 Describe bilirubin metabolism,enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia. PA25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences
			12-1- OBG-L OG 13.1 Labor mechanism			
16.07.2023				SUNDAY		
17.07.2023	MONDAY	PA-L PA 25.3 Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis	CLINICAL POSTING	PA-P SGD(Batch A+B) PA 7.4 Describe the effects of tumour on host including paraneoplastic syndromes. PA 7.5 Describe immunologyand the immune response to cancer. PA 8.1 Describe the diagnostic role of cytology and its application in clinical care. PA8.2 Describe the basis of exfoliative cytology including the techniques and stains used. OPA 8.3. Observe a diagnostic cytology and its staining and interpret the specimen	PH-P (Batch A)-2.2 Prepare oral rehydration solution from ORS packet and explain its use	PA-P SGD (Batch B) PA25.1 Describe bilirubin metabolism,enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia. PA25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequencesPA 2.5.3 Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis
18.07.2023	TUESDAY	PHL-1.19 PS-8.4,8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-pileptics drugs)		SDL-3-1.24 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs affecting renal systems including diurettics, antidiurettics-vasopressin and analogues	A	ЕТСОМ
19.07.2023	WEDNESDAY	PA-L PA 25.4 Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis. Pa25.5. Describe the etiology, pathogenesis and complications of portal hypertension. Describe Hepatocellular Carcinoma		SDL-3-1.24 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs affecting renal systems including diurettics, antidiuretics-vasopressin and analogues	PA-P SGD (Batch A)PA 25.4 Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis. Pa25.5. Describe the etiology, pathogenesis and complications of portal hypertension. Describe Hepatocellular Carcinoma	MI-P SGD MI2.7 NACO strategy for HIV diagnosis Modalities used for diagnosis of HIV & HAART regimen
20.07.2023	THURSDAY	MI-LIntegration MI3.1 Viruses causing diarrhoea (General Medicine)Integration MI3.5 Food poisoning -1 / MI3.6 Acid peptic disease Helicobacter pylori (SGD) (Pharmacology)		FM8.2, 3 & 8.6,7 & 8 Lecture 12. Define the terms Toxicology, Forensic Toxicology, Clinical Toxicology and poison Describe the various types of poisons, Toxicokinetics, and Toxicodynamics and diagnosis of poisoning in living and dead. Describe the general symptoms, principles of diagnosis and management of common poisons encountered in India Describe simple Bedside clinic tests to detect poison/drug in a patient's body fluids	PH-P (Batch B)-2.2 Prepare oral rehydration solution from ORS packet and explain its use	PA-P SGD (Batch A) PA25.1 Describe bilirubin metabolism,enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia. PA25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequencesPA 2.5.3 Describe the etiology and pathogenesis of viral and toxic hepatitis : distinguish the causes of hepatitis based on clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis
21.07.2023	FRIDAY	MI-Lintegration Mi3.7 Viral hepatitis Hepatitis -B (General Medicine) (Pathology)		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Airborne infections & Exanthematous fevers: Measles, Mumps, Rubella	PA-P SGD (Batch B)PA 25.4 Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis. Pa25.5. Describe the etiology, pathogenesis and complications of portal hypertension. Describe Hepatocellular Carcinoma	MI-P SGD SGD MI2.7 NACO strategy for HIV diagnosis Modalities used for diagnosis of HIV & HAART regimen

22.07.2023	SATURDAY	SUR-LArterial diseases SUZ7.1 Describe the etiopathogenesis, clinical features, investigations and principles of treatment of occlusive arterial disease, SUZ7.3 Describe clinical features, investigations and principles of management of vasospastic disorders	PH-L-1.19 PS-8.4,8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-Indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) 11-12 MED-L IM 3.2,3.3 Etiopathogenesis of various types of pneumonia, presentation, natural history and complications 12-1- OBG-L OG 13.1 Management of labor 1st stage with, partogram, intrapartum monitoring of fetal wellbeing and labor analgesia	MI-P Integration MI3.7 Other agents (Viruses)causing Hepatitis (General Medicine) (Pathology)	MI-L MI3.7 Other agents (parasites)causing Hepatitis	PH-L-1.19 PS-8.4,8.6 Describe the mechanism /s of action, types, doses, side effects, Indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti- epileptics drugs)
23,07,2023				SUNDAY		
24.07.2023	MONDAY	PA-L PA26.1 Define and describe the etiology,types,pathogenesis,stages, morphology and complications of pneumonia. PA 26.2 Describe the etiology,gross and microscopic appearance and complications of lung abscess. PA26.4 Define and describe the etiology,types,pathogenesis,stages morphology,microscopic appearance and complications of tuberculosis	CLINICAL POSTING	PA-P SGD (Batch A+B) PA 25.6 Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from nonobstructive jaundice based on clinical features and liver function tests	PH-P-(Batch A)-3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient	PA-P SGD (Batch B) PA(23.3) (1) Describe and interpret the abnormalities in liver function tests. Case based learning Of Hepatitis, Obstructive jaundice, Hemolytic jaundice. Interpretation of charts of liver disorders
25.07.2023	TUESDAY	PH-L L-1.19 PS-8.4,8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epielptics drugs)		PH-P-T-1.19 PS-8.4.8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)	A	ЕТСОМ
26.07.2023	WEDNESDAY	PA-L PA 26.3 Define and describe the etiology,types,pathogenesis,stages morphology and complications and evaluation of Obstructive airway disease and bronchiectasis. PA26.5 :Define and describe the etiology,types,exposure,environmental influence.pathogenesis,stages,morphology,micro scopic appearance and complications of Occupational lung disease		PH-P-SGD-1.19 PS-8.4,8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)	describe the	MI-P SGD case discussion and diagnosis of viral hemorragic fever, rheumatic fever and other related cases
27.07.2023	THURSDAY	Mi-LMI4.1 Anaerobic infections-different methods of anaerobiosis Spore bearing and non-spore bearing anaerobes, Clostridia		FM9.4 Lecture 13. Describe General Principles and basic methodologies in treatment of poisoning: decontamination, supportive therapy, antidote therapy, procedures of enhanced elimination with regard to Ethanol, methanol, ethylene glycol, Intergrated to Medicine Dept.		PA-P SGD (Batch A) PA(23.3) (1) Describe and interpret the abnormalities in liver function tests. Case based learning Of Hepatitis, Obstructive jaundice, Hemolytic jaundice. Interpretation of charts of liver disorders
28.07.2023	FRIDAY	MI-Lintegration MI4.1 Gas gangrene (General Med		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Alfborne infections & Exanthematous fevers: Diphtheria, Pertussis, Tetanus	PA-P SGD (Batch B)PA26.1 Define and describe the etiology,types,pathogenesis,stages ,morphology and complications of pneumonia. PA 26.2 Describe the etiology,gross and microscopic appearance and complications of lung abscess. PA26.4 Define and describe the	MI-P SGD case discussion and diagnosis of viral hemorragic fever, rheumatic fever and other related cases
29.07.2023	SATURDAY			MOHARRAM		
30.07.2023				SUNDAY		

31.07.2023	MONDAY	PA-L PA 26.6: Define and describe the etiology,types,exposure, genetics, environmental influences, pathogenesis, stages, morphology,micr oscopic appearance, metastases and complications of tumours of the lung and pleura.PA26.7: Define and describe the etiology,types,exposure, genetics, environmental influences, pathogenesis, stages, morphology,micr oscopic appearance and complications of Mesothelioma.	CLINICAL POSTING	PA-P SGD (Batch A+ B) PA 12.1 Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohol.	PH-P -(Batch A)-3.2 Perform and interpret a critical appraisal (Audit) of a given prescription	PA-P SGD (Batch B) PA 26.3 Define and describe the etiology,types,pathogenesis,stages morphology and complications and evaluation of Obstructive airway disease and bronchiectasis. PA26.5 : Define and describe the etiology,types,exposure,environmental influence,pathogenesis,stages,morphology,microscopic appearance and complications of Occupational lung diseasePA 26.6 : Define and describe the etiology,types,exposure,genetics,environmental influences,pathogenesis,stages,morphology,microscopic appearance,metastases and complications of tumours of the lung and pleura.PA26.7 :Define and describe the etiology,types.exposure,genetics,environmental influences,pathogenesis,stages,morphology,microscopic appearance and complications of Mesothelioma.
				August-2023		
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00
01.08.2023	TUESDAY	PH-L L-1.19 PS-8.4,8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)	CLINICAL POSTING	PH-P T -1.16 Describe mechanism/ s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacolds, including: anti-histaminic, 5-HT modulating drugs, NSAIDs, drugsfor gout, anti rheumaticdrugs, drugs for migraine	AETCOM	
02.08.2023	WEDNESDAY	PA-L PA27.1 Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis PA27.2: Describe the etiology, dynamics, pathology (types and complications of aneurysms including aortic aneurysms Pa 27.10 Describe the etiology, pathophysiology,pathology features and complications of syphilis on the cardiovascular system		PH-T-1.19 PS-8.4.8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)	PA-P SGD (Batch A)PA27.1 Distinguish atteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis PA27.2: Describe the etiology,dynamics,pathology types and complications of aneurysms including aortic aneurysms Pa 27.10 Describe the etiology, pathophysiology,pathology features and complications of syphilis on the cardiovascular system	MI-P SGD Formative assessment II
03.08.2023	THURSDAY	MI-Lintegration MI4.1 Tetanus & Botulism (Genera		FM10.1 Lecture 14. Describe General Principles and basic methodologies in treatment of poisoning: decontamination, supportive therapy, antidote therapy, procedures of enhanced elimination with regard to: 1. Antipyretics – Paracetamol, Salicylates ii. Anti-Infectives (Common antibiotics – an overview) iii. Neuropsychotoxicology Barbiturates, benzodiazepins phenytoin, lithium, haloperidol, neuroleptics, tricyclics Intergrated to Medicine dept.	PH-P -(Batch B) 3.2 Perform and interpret a critical appraisal (Audit) of a given prescription	PA-P SGD (Batch A) PA 26.3 Define and describe the etiology,types,pathogenesis,stages morphology and complications and evaluation of Obstructive airway disease and bronchiectasis. PA26.5 : Define and describe the etiology,types,exposure,environmental influence,pathogenesis,stages,morphology,microscopic appearance and complications of Occupational lung diseasePA 2.6.6 : Define and describe the etiology,types,exposure,genetics,environmental influences,pathogenesis, stages,morphology,microscopic appearance,metastases and complications of tumours of the lung and pleura.PA26.7 : Define and describe the etiology,types,exposure,genetics,environmental influences,pathogenesis,stages,morphology,microscopic papearance,metastases and complications of tumours of the lung and pleura.PA26.7 : Define and describe the etiology,types,exposure,genetics,environmental influences,pathogenesis,stages,morphology,microscopic appearance and complications of Mesothelioms.
04.08.2023	FRIDAY	MI-L MI4.1 Antibiotic associated colitis Non sporing anaerobes		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Airborne infections & Exanthematous fevers: ARI, Influenza	PA-P SGD (Batch B)PA27.1 Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis PA27.2: Describe the etiology, dynamics, pathology types and complications of aneurysms including aortic aneurysms Pa 27.10 Describe the etiology, pathophysiology, pathophysiology, pathopy features and	MI-P SGD Formative assessment II
05.08.2023	SATURDAY	SUR-LGangrene and Amputations SU27-4 Describe the types of gangrene and principles of amputation	10-11 PH-L L-1.20 + 1.21 1.20 Describe the effects of acute and chronic Ethanol intake 1.21 Describe the symptoms and management of methanol and ethanol poisonings	MI-P Integration MI4.2 Bone and joint infections-Prosthetic joint infections, Acinetobacter (Orthopaedics)	PH-L 1.22+ 1.23 1.22. Describe drugs of abuse (dependenc e, addiction, stimulants,d epressants, psychedelic s, drugs used for criminal offences) 1.23. Describe the process and mechanism of drug de-addiction	PA-L PA27.4 Describe the etiology,pathophysiology, pathology,gross and microscopic features,criteria and complications of Rheumatic fever. PA 27.6Describe the etiology,pathophysiology, pathology,gross and microscopic features,diagnosis and complications of Infective endocarditis.

1	1					
			11-12 MED-L IM 3.1			
			community acquired pneumonia, nosocomial pneumonia and aspiration pneumonia			
			production production			
			12-1-OBG-L OG 13.1 Management of labor 2nd and third stage			
06.08.2023				SUNDAY		
07.08.2023	MONDAY	PA-L PA 27.3 Describe the etiology, types,stages,pathophysiology, pathology,and complications of Heart Failure. PA 27.5: Describe the epidemiology,risk factors ,etiology,pathophysiology, pathology,presentations gross and microscopic features, diagnostic tests and complications of Ischaemic Heart Disease.	CLINICAL POSTING	PA-P SGD (Batch A-B) :PA12.2 Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation. PA 12.3: Describe the pathogenesis of obesity and its consequences.	critical appraisal (Audit) of a given	PA-P SGD (Batch - B)PA 27.3 Describe the etiology, types, stages, pathophysiology, pathology, and complications of Heart Failure. PA 27.5 : Describe the epidemiology, risk factors , etiology, pathophysiology, pathology, presentations gross and microscopic features, diagnostic tests and complications of Ischaemic Heart Disease. PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes. Interpretation of chart of Acute Myocardial infarction
08.08.2023	TUESDAY	PH-L -1.34 IM-15.15 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid- peptic disease and GERD 2. Antiemetics 3. Antidiarrhoeals and 4. Laxatives 5. Inflammator y Bowel Disease 6. Irritable Bowel Disorders, biliary and prokinetics		PH - P -SDL-4 -1.16 Describe mechanism/ s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including; anti-histaminic, 5-HT modulating drugs, NSAIDs, drugs for gout, anti rheumatic drugs, drugs for migraine	A	NETCOM
09.08.2023	WEDNESDAY	PA-L PA 27.7 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of Pericarditis and pericardial effusion, PA 27.9 : Classify and describe the etiology,types pathophysiology, pathology, presentations gross and microscopic features, diagnosis and complications of		PH - P -SDL-4 -1.16 Describe mechanism/ s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autaciós, including: anti-histaminic, 5-HT modulating drugs, NSAIDs, drugs for gout, anti rheumatic drugs , drugs for migraine	PA-P SGD (Batch A)A 27.7 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of Pericarditis and pericardial effusion, PA 27.9 : Classify and describe the etiology,types pathophysiology, pathology, presentations gross and microscopic features, diagnosis and	MI-P SGD MI3.8 Case discussion Serological diagnosis of viral hepatitis OSPE
10.08.2023	THURSDAY	MI-L Integration MI4.3 Skin and soft tissue infectio		FM11.1 Lecture 15 Describe features and management of Snake bite, scorpion sting, bee and wasp sting and spider bite	PH-P (Batch B)-3.2 Perform and interpret a critical appraisal (Audit) of a given prescription	PA-P SGD (Batch -A)PA 27.3 Describe the etiology, types, stages, pathophysiology, pathology, and complications of Heart Failure, PA 27.5: Describe the epidemiology, risk factors, etiology, pathophysiology, pathology, presentations gross and microscopic features, diagnostic tests and complications of Ischaemic Heart Disease. PA 27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes.Interpretation of chart of Acute Myocardial Infarction
11.08.2023	FRIDAY	MI-L Integration MI4.3 Leprosy (Dermatology)		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases: AGE, Food poisoning	PA-P SGD (Batch B) A 27.7 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of Pericarditis and pericardial effusion. PA 27.9 : Classify and describe the etiology,types pathophysiology, pathology,presentations gross and microscopic features, diagnosis and	MI-P SGD MI3.8 Case discussion Serological diagnosis of viral hepatitis OSPE
12.08.2023	SATURDAY	SUR-LVenous and Lymphatic diseases SU27.5 Describe the applied anatomy of venous system of lower limb SU27.6 Describe pathophysiology, clinical features, Investigations and principles of management of DVT and Varicose veins SU27.7 Describe pathophysiology, clinical features, investigations and principles of management of Lymph edema, lymphangitis and Lymphomas	PH-L -1.34 IM-15.15 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Actic peptic disease and GERD 2. Antiemetics 3.Antidiarrhoeals and 4.Laxatives 5. Inflammator y Bowel Disease 6.Irritable Bowel Disorders, biliary and prokinetics 11-12 MED-L IM 3.15; 3.16 community acquired pneumonia the indications for hospitalization, Investigations,	MI-P Integration MI4.3 Superficial, cutaneous and sub-cutaneous fungal infections (Dermatology)	PA-L PA 28.1 Describe the normal histology of the Kidney, PA 28.2 Define, classify and distiguish the clinical syndromes and describe the etiology, pathophysiology, pathology, morphology, clinical and laboratory and urinaryfindings and complications of Renal Failure. PA 28.3: Define and Describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of Acute Renal Failure. PA 28.4: Define and Describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of Chronic Renal Failure	PH-L -1.34 IM-15.15 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics 3.Antidiarrhoeals and 4.Laxatives 5. Inflammator y Bowel Disease 6.Irritable Bowel Disorders, billiary and prokinetics
13.08.2023				SUNDAY		

14.08.2023	MONDAY	PA-L PA 28.5: Define and classify glomerular diseases. Enumerate and describe the etiology, precipitating factors, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis. PA 28.6: Define and Describe the etiology, pathogenesis, pathology, laboratory urinary findings, progression and complications of IgA Nephropathy. PA28.7: Enumerate and describe the findings in glomerular manifestations of systemic disease	CLINICAL POSTING	PA-P SDL (Batch A +B) A27.1 Distinguish arteriosclerosis from atherosclerosis. Describe the pathogenesis and pathology of various causes and types of arteriosclerosis PA27.2: Describe the etiology, dynamics, pathology types and complications of aneurysms including aortic aneurysms Pa27.10 Describe the etiology, pathophysiology, pathology features and complications of syphilis on the cardiovascular system, PA 27.3 Describe the etiology, types, stages, pathophysiology, pathology, pathology, risk factors, etiology, pathophysiology, pathology, prestrations gross and microscopic features, challenges, PA27.4 Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications of Ischaemic Heart Disease, PA27.4 Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria and complications of Rheumatic fever. PA 27.6 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of Infective endocarditisPA 27.7 Describe the etiology, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of Pericarditis and pericardial effusion. PA 27.9: Classify and describe the etiology, types pathophysiology, pathology, presentations gross and microscopic features, diagnosis and complications of Cardiomyopathies.	PH-P (Batch A) -3.7 Prepare a list of Essential Medicines for health care facility	PA-P SGD (Batch B) PA 28.1 Describe the normal histology of the Kidney, PA 28.2 Define, classify and distiguish the clinical syndromes and describe the etiology, pathophysiology, pathology, morphology.clinical and laboratory and urinaryfindings and complications of Renal Failure. PA 28.3: Define and Describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of Acute Renal Failure. PA 28.4: Define and Describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of Chronic Renal Failure.
15.08.2023	TUESDAY			INDEPENDENCE DAY		
16.08.2023	WEDNESDAY			PARSI NEW YEAR		
17.08.2023	THURSDAY	MI-L Integration MI4.3 Mycetoma, Actinomycosis (Dermatology)	CLINICAL POSTING	FM8.4 SDL -4 Describe the Laws in relations to poisons including NDPS Act, Medico-legal aspects of poisons	PH-P (Batch B) -3.7 Prepare a list of Essential Medicines for health care facility	PA-P SGD(Batch A.) PA 28.1 Describe the normal histology of the Klidney, PA 28.2 Define, classify and distiguish the clinical syndromes and describe the etiology, pathophysiology, pathology, morphology,clinical and laboratory and urinaryfindings and complications of Renal Failure. PA 28.3: Define and Describe the etiology, precipitating factors,pathogenesis, pathology, laboratory urinary findings, progression and complications of Acute Renal Failure. PA 28.4: Define and Describe the etiology, precipitating factors,pathogenesis, pathology, laboratory urinary findings, progression and complications of Chronic Renal Failure
18.08.2023	FRIDAY	MI-L Integration MI4.3 Mycetoma, Actinomycosis (Dermatology). Integration MI4.3 Other viral exanthematous fevers.		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases: Infective hepatitis	PA-P SGD (Batch B)PA 28.5: Define and classify glomerular diseases. Enumerate and describe the etiology, precipitating factors, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulanephritis. PA 28.6: Define and Describe the etiology, pathogenesis, pathology, laboratory unirary findings, progression and complications of IgA Nephropathy. PA26.7: Enumerate and describe the findings in glomerular	MI-P SGD MI4.1 Method of sample collection and transportation to lab for anaerobic infections(DOAP)
19.08.2023	SATURDAY	SUR-LMinimal Invasive Surgery SU15.1 Describe indicationsadvantages and disadvantages of Minimally invasive GeneralSurgery	PH-L -1.34 IM-15.15 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics 3.Antidiarrhoeals and 4.Laxatives 5. Inflammator y Bowel Disease 6.Irritable Bowel Disorders, biliary and prokinetics 11-12 MED_L IM 3.17; 3.19 Management of Pneumonia, Preventive aspects	MI-P Integration Parasitic infections of skin soft tissue (Jarva migrans) (Dermatology) and miscellaneous	MI-L Formative assessment III Skin soft Tissue, CVS, Anaerobes	PA-LPA 28.8: Enumerate and classify diseases affecting tubular interstitium. PA 28.9 Define and describe the etiology, pathogenesis, pathology, laboratory urinary findings,progression and complications of Acute tubular necrosis. PA 28.10 Describe the etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Acute and Chronic pyelonephritis and reflux nephropathy. PA28.13: Define.classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of renal stone disease and obstructive uropathy

I	1		12-1-OBG-L OG 17.1, 17.2 lactation physiology and management			
20.08.2023				SUNDAY		
21.08.2023	MONDAY	PA-L PA 28.11 Define, classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of Vascular disease of the kidney. PA 28.12 Define, classify and describe the genetics, inheritance etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Cystic disease of the Kidney. PA28.15: Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies	CLINICAL POSTING	PA-P SGD (Batch A+B) PA 23.3 (II) Describe and interpret abnormalities in renal function tests. Charts: Interpretation of Renal Disorders		PA-P SGD (Batch B)8.8: Enumerate and classify diseases affecting tubular interstitium. PA 28.9 Define and describe the etiology, pathogenesis, pathology, laboratory urinary findings,progression and complications of Acute tubular necrosis. PA 28.10 Describe the etiology, pathogenesis, pathology, laboratory urinary findings,distiguishing features, progression and complications of Acute and Chronic pyelonephritis and reflux nephropathy. PA28.13: Define,classify and describe the etiology,pathogenesis,pathology, laboratory urinary findings,distinguishing features,progression and complications of renal stone disease and obstructive uropathy
22.08.2023	TUESDAY	PH-L -1.34 IM-15.15 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics 3.Antidiarrhoeals and 4.Laxatives 5. Inflammator y Bowel Disease 6.Irritable Bowel Disorders, biliary and		PH-P SDL-5-1.19 PS-8.4.8.6 Describe the mechanism/s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)	А	ETCOM
23.08.2023	WEDNESDAY	PA-L PA 28.14: Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features, progression and spread of Renal Tumours. PA 28.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of Urothelial tumours.		PH-P SDL- 5 - 1.19 PS-8.4.8.6 Describe the mechanism /s of action, types, doses, side effects, indications and contra-indications of the drugs which act on CNS (anxiolytics, sedatives and hypnotics antipsychotic, anti-depressant drugs, anti-maniacs opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)	PA-P SGD (Batch A)PA 28.5 : Define and classify glomerular diseases. Enumerate and describe the etiology, precipitating factors, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis. PA 28.6: Define and Describe the etiology, pathogenesis, pathology, laboratory urinary findings, progression and complications of IgA Nephropathy. PA26.7: Enumerate and describe the findings in glomerular	MI-P SGD Integration MI4.3 Laboratory diagnosis of skin and soft tissue infections (SGD) (Dermatology)
24.08.2023	THURSDAY	MI-L Integration MI6.1 Upper respiratory tract infections-Introduction, bacterial pharyngitis Diphtheria, (General Medicine)		FM14.21, 8.9, 8.10,9.1, 9.2,9.3. SDG-11 To collect, preserve, seal and dispatch exhibits for DNA-Finger printing using various formats of different laboratories. Describe the procedure of intimation of suspicious cases or actual cases of foul play to the police, maintenance of records, preservation and dispatch of relevant samples for laboratory analysis.FM8.10 Describe the general principles of Analytical Toxicology and give a brief description of analytical methods available for toxicological analysis: Chromatography — Thin Layer Chromatography (Gas Chromatography, Liquid Chromatography and Atomic Absorption Spectroscopy, Describe General Principles and basic methodologies in treatment of poisoning: decontamination, supportive therapy, antitode therapy, procedures of enhanced elimination with regard to: Caustics	PH-P (Batch B) 3.3 Perform the critical evaluation of the drug promotional literature	PA-P SGD (Batch A)PA28.8 : Enumerate and classify diseases affecting tubular interstitium. PA 28.9 Define and describe the etiology, pathogenesis, pathology, laboratory urinary findings,progression and complications of Acute tubular necrosis. PA 28.10 Describe the etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Acute and Chronic pyelonephritis and reflux nephropathy. PA28.13 : Define, classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of renal stone disease and obstructive uropathy
25.08.2023	FRIDAY	MI-L MI6.1 Laboratory diagnosis of URTI(DOAP) Diphteria, strept, Yeast (General Medicine)		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases: Typhoid, Cholera	PA-P SGD (Batch B).PA 28.11 Define, classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of Vascular disease of the kidney. PA 28.12 Define, classify and describe the genetics, inheritance etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Cystic disease of the Kidney. PA28.15: Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies 28.14: Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features. progression and spread of Renal Tumours. PA 28.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features.	MI-P SGD Integration MI4.3 Laboratory diagnosis of skin and soft tissue infections (SGD) (Dermatology)
26.08.2023	SATURDAY	SUR-LSkin and subcutaneous tissue SU18.1 Describe the pathogenesis, clinical features and management of various cutaneous and subcutaneous infections. SU18.2 Classify skin tumorsDifferentiate different skin tumors and discuss their management	PH-L-1.32 CT-2.16 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in bronchial asthma and COPD	MI-P Integration MI6.1 Orthomyxo virus (General Medicine) (Paediatrics)	MI-L Integration, MI6.1 Paramyxo virus (General Medicine) (Paediatrics)	PH L 1.33 CT-2.16 Describe the mechanism of action, types, doses, side effects, indications and contraindications of the drugs used in cough (antitussives, expectorant s/ mucolytics)

			11-12 MED-L M 20.1; 20.3; 20.7 Snake Bite 12-1-OG 9.5-Hyperemesis , vomiting in pregnancy management			
27.08.2023				SUNDAY		
28.08.2023	MONDAY	PAL. PA 29.1: Classify Testicular tumours and describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumours PA 29.2: Describe the ,pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of Carcinoma of Penis. PA29.3: Describe the ,pathogenesis, pathology, hormonal dependency, presenting and distinguishing features, urologic findings and diagnostic tests of Benign Prostatic Hyperplasia. PA29.4 Describe the ,pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of Carcinoma of Prostate.PA29.5 Describe the etiology, pathogenesis, pathology, and progression of Prostatitis	CLINICAL POSTING	PA.P SDL.PA 28.1 Describe the normal histology of the Kidney. PA 28.2 Define, classify and distiguish the clinical syndromes and describe the etiology, pathophysiology, pathology, morphology, clinical and laboratory and urinaryfindings and complications of Renal Failure. PA 28.3: Define and Describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of Acute Renal Failure. PA 28.4: Define and Describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of Chronic Renal Failure PA 28.5: Define and Describe the etiology, precipitating factors, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis. PA 28.6: Define and Describe the etiology, pathogenesis, pathology, laboratory urinary findings, progression and complications of IgA Nephropathy. PA28.7: Enumerate and describe the findings in glomerular manifestations of systemic disease	PH-P-(Batch A) 3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch B)PA 29.1 : Classify Testicular tumours and describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumours PA 29.2: Describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of Carcinoma of Penis. PA29.3: Describe the, pathogenesis, pathology, hormonal dependency, presenting and distinguishing features, urologic findings and diagnostic tests of Benign Prostatic Hyperplasia. PA29.4 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of Carcinoma of Prostate.PA29.5Describe the etiology, pathogenesis, pathology, and progression of Prostatitis
29.08.2023	TUESDAY	PH-L-1.38 Describe the mechanism of action, type		PH-P-SGD -1.34 IM-15.15 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics and prokinetics	,	AETCOM
30.08.2023	WEDNESDAY			RAKSHABANDHAN		
31.08.2023	THURSDAY	MI-L Integration MI6.1 Viral pharyngitis EBV, Adenovirus, Rhinovirus, (SGD) (General Medicine) (Paediatrics)	CLINICAL POSTING	FM9.4 9.5, 9.6,10.1,12.1& 13.2 Describe General Principles and basic methodologies in treatment of poisoning: decontamination, supportive therapy, antidote therapy, procedures of enhanced elimination with regard to Organophosphates, Carbamates, Organochlorines, Pyrethroids, Paraquat, Aluminium and Zinc phosphcribe General Principles and basic methodologies in treatment of poisoning; decontamination, supportive therapy, antidote therapy, procedures of enhanced elimination with regard to Ethanol, methanol, ethylene glycol. Describe General Principles and basic methodologies in treatment of poisoning: decontamination, supportive therapy, antidote therapy, procedures of enhanced elimination with regard to Ammonia, carbon monoxide, hydrogen cyanide & derivatives, methyl isocyanate, tear (riot control) gases. Describe General Principles and basic methodologies in treatment of poisoning; decontamination, supportive therapy, antidote therapy, procedures of enhanced elimination with regard to:Describe features and management of abuse/poisoning with following chemicals: Tobacco, cannabis, amphetamines, cocaine, hallucinogens, designer	PH-P-(Batch B)3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch A)A 29.1: Classify Testicular tumours and describe the, pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumours PA 29.2: Describe the , pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of Carcinoma of Penis. PA29.3: Describe the , pathogenesis, pathology, hormonal dependency, presenting and distinguishing features, urologic findings and diagnostic tests of Benign Prostatic Hyperplasia. PA29.4Describe the ,pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of Carcinoma of Prostate.PA29.5Describe the etiology, pathogenesis, pathology, and progression of Prostatitis

				September-2023		
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00
01.09.2023	FRIDAY	MI-L Integration Mi6.1 LRTI-introduction, bacterial pneumonia Streptococcus pneumonia, (General Medicine)	CLINICAL POSTING	CML_CM 8.1, 8.3 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Faeco-oral diseases: Polio & relevant National Health Programme	PA-P SGD (Batch A) 28.11 Define, classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of Vascular disease of the kidney. PA 28.12 Define, classify and describe the genetics, inheritance etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Cystic disease of the Kidney. PA28.15: Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies 28.14: Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features are progression and spread of Renal Tumours. PA 28.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of Urothelial tumours.	MI-P SGD MI2:3 Blood collection for culture, blood culture REPORTING, bACT/ALERT
02.09.2023	SATURDAY	SUR-LTransplantation SU13.1 Describe the immunological basis of organ transplantation SU13.2 Discuss the Principles of immunosuppressive therapy.Emunerate indications, describe surgical principles, management of organ Transplantation	PHL-1.36 IM-11.16,IM-12.13 Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis) 11-12 MED-L 12-1 OBG-L-OG-1.3, 9.1-Haemorrhage in early pregnancy (abortions)	MI-P MI6.1 H influenza	PH-L - 1.36 IM-11.16,IM-12.13 Describe the mechanism of action, types, doses, side effects ,indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)	PAL-IPA 30.1 Describe the pidemiology, pathology, screenin g, diagnosis and progression of Carcinoma of the Cervix. PA 30.2 Describe the epidemiology, pathogenesis, etiology, pathology, screenin g, diagnosis and progression and spread of Carcinoma of the Endometrium, PA30.3 Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of the leiomyomas and leiomyosarcomas. PA 30.6 Describe the etiology and morphologic features of cervicitis. PA 30.7 Describe the etiology, hormonal dependence, features and morphology of endometriosis. PA 30.8 :Describe the etiology and morphologic features of adenomyosis. PA 30.9 Describe the etiology and morphologic features of adenomyosis. PA 30.9 Describe the etiology and morphologic features of adenomyosis. PA 30.9 Describe the etiology and morphology of endometrial hyperplasia
03.09.2023				SUNDAY		
04.09.2023	MONDAY	PA-L PA 30.4 Classify and describe the etiology,pathogenesis,pathology,morphology,clin ical course,spread and complications of Ovarian tumours.PA 30.5 Describe the etiology,pathogenesis,pathology,morphology,clin ical course,spread and complications of Gestational trophoblastic Neoplasms.	CLINICAL POSTING	PA.P SDL (BATCH A+ B)PA28.8: Enumerate and classify diseases affecting tubular interstitium. PA 28.9 Define and describe the etiology, pathogenesis, pathology, laboratory urinary findings,progression and complications of Acute tubular necrosis. PA 28.10 Describe the etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Acute and Chronic pyelonephritis and reflux nephropathy. PA28.13: Define, classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of renal stone disease and obstructive uropathy28.11 Define, classify and describe the etiology, pathogenesis, pathology, laboratory urinary findings, distinguishing features, progression and complications of Vascular disease of the kidney. PA 28.12 Define, classify and describe the genetics, inheritance etiology, pathogenesis, pathology, laboratory urinary findings, distiguishing features, progression and complications of Vascular disease of the Kidney. PA28.15: Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies 28.14: Classify and describe the etiology, genetics, pathogenesis, pathogenesis, pathogenesis, pathogenesis presenting features and progression of thrombotic angiopathies 28.14: Classify and describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of Urothelial tumours.	PH-P-(Batch A) - 3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch B)PA 30.1 Describe the epidemiology, pathogenesis, etiology, pathology, screenin g, diagnosis and progression of Carcinoma of the Cervix, PA 30.2 Describe the epidemiology, pathogenesis, etiology, pathology, screenin g, diagnosis and progression and spread of Carcinoma of the Endometrium, PA30.3 Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of the leiomyomas and leiomyosarcomas.PA 30.6 Describe the etiology and morphologic features of cervicitis. PA 30.7 Describe the etiology, hormonal dependence, features and morphology of endometriosis. PA 30.8 : Describe the etiology and morphology of endometriosis. PA 30.8 : Describe the etiology and morphology, hormonal dependence and morphology of endometrial hyperplasia

05.09.2023	TUESDAY	PH- L - 1.36 [M-11.16, [M-12.13 Describe the mechanism of action, types, doses, side effects indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)		PH-P 1.34 (SDL-6 Describe the mechanism/s of action, types, doses, side effects, indications and contraindicat ions of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics and prokinetics	A	ETCOM
06.09.2023	WEDNESDAY	PA-L		PH-P 1.34 (SDL-6 Describe the mechanism/s of action, types, doses, side effects, indications and contraindicat ions of the drugs used as below: 1. Acid-peptic disease and GERD 2. Antiemetics and prokinetics	PA-P SGD (Batch A)PA 30.4 Classify and describe the etiology,pathogenesis,pathology,morphology, clinical course,spread and complications of Ovarian tumours.PA 30.5 Describe the etiology,pathogenesis,pathology,morphology, clinical course,spread and complications of Gestational tronpholbastir. Neonlasms.	MI-P SGD MI6.1 Laboratory Diagnosis of Mycobacterium tuberculosis (General Medicine)
07.09.2023	THURSDAY	MI-L Integration MI6.1 Viral pneumonia Atypical pneumonia (SGD) (General Medicine)		FM13.1 SDL 5 Describe toxic pollution of environment, its medico-legal aspects & toxic hazards of occupation and industry	PH-P-(Batch B)3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch A)PA 30.1 Describe the epidemiology,pathogenesis, etiology,pathology,screenin g,diagnosis and progression of Carcinoma of the Cervix. PA 30.2 Describe the epidemiology,pathogenesis, etiology,pathoglogy,screenin g,diagnosis and progression and spread of Carcinoma of the Endometrium,PA30.3 Describe the pathogenesis, etiology,pathology,diagnosis and progression and spread of the leiomyomas and leiomyosarcomas.PA 30.6 Describe the etiology and morphologic features of cervicitis. PA 30.7 Describe the etiology from an analysis of the pathogenesis and morphology of endometriosis.PA 30.8 Describe the etiology dometriosis.PA 30.9 Describe the etiology dometriosis.PA 30.9 Describe the etiology dometriosis.PA 30.9 Describe the etiology dometrial hyperplasia
08.09.2023	FRIDAY	MI-L MI 6.1 Infection due to Non fermenters and Integration MI6.1 Candidal pneumonia and ABPA (allergic bronchopulmonary aspergillosis) Pneumocystosis (General Medicine)		CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for zoonotic diseases: Rabies, Plague	PA-P SGD (Batch B)PA 30.4 Classify and describe the etiology,pathogenesis,pathology,morphology, clinical course,spread and complications of Ovarian tumours.PA 30.5 Describe the etiology,pathogenesis,pathology,morphology, clinical course,spread and complications of Gestational trophoblastic Neoplasms.	MI-P SGD MI6.1 Laboratory Diagnosis of Mycobacterium tuberculosis (General Medicine)
09.09.2023	.09.2023 SATURDAY	NY SUR-L Biohazard disposal SU15.1 Describe classification of hospital waste and appropriate methods of disposal	PH-L - 1.36 IM-11.16,IM-12.13 Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)	epidemiology,pathogenesis, etioly, screening, diagnosis and progrey Carcinoma of the Cervix. PA 30.2 epidemiology, pathogenesis etiolot, y,screening, diagnosis and progression of Carcinoma of the Endometrium. PA30.3 Describe the pathogenesis, etiology, pathology and progression and spread of the leiomyomas and leiomyosarcom. Describe the etiology and morph features of cervicitis. PA 30.7 Describe the etiology and morph features of cervicitis. PA 30.7 Describe the etiology and morph features of cervicitis. PG etiology, hormonal dependence, for morphology of endometriosis. PJ : Describe the etiology and restrictions of the passing the progression of the passing the etiology and morph features of the passing	Endometrium PA30.3 Describe the	PH-L - 1.36 [M-11.6],M-12.13 Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)
			11-12 MED-L M 21.1 to 21.3 Common plant poisons, common corrosives poisoning.		pathogenesis,etiology,pathology,diagnosis and progression and spread of the leiomyomas and leiomyosarcomas.PA 30.6 Describe the etiology and morphologic features of cervicitis. PA 30.7 Describe the etiology,hormonal dependence,features and morphology of endometriosis. PA 30.8 :Describe the etiology and morphologic features of adenomyosis.PA 30.9 Describe the	
			12-1 OBG-L -OG-9.3-Haemorrhage in early pregnancy (ectopic pregnancy)		etiology,hormonal dependence and morphology of endometrial hyperplasia PA 30.4 Classify and describe the etiology,pathogenesis,pathology,morphology, clinical course,spread and complications of Ovarian tumours.PA 30.5 Describe the etiology,pathogenesis,pathology,morphology, clinical course,spread and complications of Gestational tropholblastic. Neonlasms	
10.09.2023				SUNDAY		
11.09.2023	MONDAY	PA-L PA31.1 Classify and describe the types, etiology, pathogenesis, pathology and hormonal dependency of benign breast disease. PA 31.2 Classify and describe the epidemiology, pathogenesis, classification, morphology, prognostic factors, hormonal dependency, staging and spread of Carcinoma of the Breast. PA 31.4 Enumerate and describe the etiology, hormonal dependency and pathogenesis of gynaecomastia.	CLINICAL POSTING	PA-P SGD (Batch A + B) PA10.1 : Define and describe the pathogenesis and pathology of malaria. PA10.2 Define and describe the pathogenesis and pathology of Cysticercosis.PA10.3 Define and describe the pathogenesis and pathology of Leprosy.	PH-P-(Batch A) 3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch B) PA 10.4 Define and describe the pathogenesis and pathology of common bacterial,viral,protozoal and helminthic diseases.
12.09.2023	TUESDAY	PH-L-1.37 Describe the mechanisms of action,types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones		PH-P-SDL-7-1.32 CT-2.16 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in bronchial asthma and COPD	A	ETCOM

13.09.2023	WEDNESDAY	PA-L PA32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings. PA32.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis. Pa32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/		PH.P-SDL-7-1.32 CT-2.16 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in bronchial asthma and COPD	PA-P SGD (Batch A)PA31.1 Classify and describe the types, etiology, pathogenesis, pathology and hormonal dependency of benign breast disease. PA 31.2 Classify and describe the epidemiology, pathogenesis, classification, mor phology, prognostic factors, hormonal dependency, staging and spread of Carcinoma of the Breast. PA 31.4 Enumerate and describe	MI-P SGD 3 Interpretation of the reports -I SGD)		
14.09.2023	THURSDAY		POLA					
15.09.2023	FRIDAY	MI-L Integration MI7.1 Genital infections Gonorrhoea (Dermatology) (OBGY)	CLINICAL POSTING	CM-L CM 8.1 Epidemiological characteristics and control measures including the use of essential laboratory tests at the primary care level for Emerging and re-emerging diseases: Ebola, Nipah, COVID-19	PA-P SGD (Batch B) PA31.1 Classify and describe the types, etiology, pathogenesis, pathology and hormonal dependency of benign breast disease. PA 31.2 Classify and describe the epidemiology, pathogenesis, classification, morphology, prognostic factors, hormonal dependency, staging and spread of Carcinoma of the Breast. PA 31.4 Enumerate and describe the etiology, hormonal dependency and pathogenesis of gynaecomastia.	MI-P SGD 3 Interpretation of the test -II (SGD)		
16.09.2023	SATURDAY	SUR-LSurgical Audit and Research SU7.1 Describe the Planning and conduct of Surgical audit. SU7.2 Describe the principles and steps of clinical research in General Surgery	PH-L-1.37 Describe the mechanisms of action,types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones	MI-P Integration MI7.2 Sexually transmitted infections-1 syphillis (OBGY) (Dermatology)	MI-L Integration MI7.1 Genital infections Non gonococcal urethritis LGV, Trichomoniasis, Bacterial vaginosis (Dermatology) (OBGY)	PA-L PA 32.4 Classify and describe the epidemiology,etiology,pathogenesis,pathology,clinical laboratory features,complications and progression of Diabetes Mellitus.		
			11-12 MED-L IM 21.4 Commonly observed drug overdose and approach to therapy					
			12-1-OG- 9.4 Hemorrhage in early pregnancy (Molar pregnancy)					
17.09.2023				SUNDAY				
18.09.2023	MONDAY	PA-L PA 32.5 Describe the etiology,genetics,pathogenesis,manifestations,la boratory and morphologic features of Hyperparathyroidism. PA 32.6 Describe the etiology, pathogenesis, manifestations, laboratoryfindings, morphologic features,complications and metastases of pancreatic cancer	CLINICAL POSTING	PA-P SGD (Batch A + B) PA 32.4 Classify and describe the epidemiology,etiology,pathogenesis,pathology,clinical laboratory features,complications and progression of Diabetes Mellitus. Investigations in Diabetes Mellitus . Glucose tolerance Charts of Diabetes Mellitus, Renal Glycosuria, Normal GTT, Latent Diabetes.	PH-P-(Batch A)3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch B)PA32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings, PA32.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis, Pa32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/ hypothyroidism.		
19.09.2023	TUESDAY			GANESH CHATURTHI				
20.09.2023	WEDNESDAY	PA-L PA 32.7 : Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Adrenal Insufficiency PA 32.8 : Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Cushing's syndrome.PA 32.9 : Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Adrenal Neoplasms.	CLINICAL POSTING	PH-T-1.37 Describe the mechanisms of action,types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones	PA-P SGD (Batch A) PA23.3 (III) Describe and interpret abnormalities in thyroid function tests. Interpretation of thyroid disorders	MI-P SGD MI6.2 Gram staining- Interpretation of results		
21.09.2023	THURSDAY	MI-L Integration MI7.3 Urinary tract infections (General Medicine)		SGD- FM 14.2, 14.3, 14.6,14.7,14.8,14.16 Demonstrate the correct technique of clinical examination in a suspected case of poisoning & prepare medico-legal report in a simulated/ supervised environment. Assist and demonstrate the proper technique in collecting, preserving and dispatch of the exhibits in a suspected case of poisoning, along with clinical examination. Demonstrate and interpret medico-legal aspects from examination of hair (human & animal) fibre, semen & other biological fluids. Demonstrate & identify that a	PH-P-(Batch B)3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch A)PA32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings, PA32.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis.Pa32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/ hypothyroidism.		

22.09.2023	FRIDAY	MI-L Integration MI7.3 Urinary tract infections (General Medicine)		CM-P CM 8.3, 8.4 Preparation of epidemic curve/spot map with the help of given data and its interpretation; NHP spotters demonstration	PA-P SGD(Batch B) PA23.3 (III) Describe and interpret abnormalities in thyroid function tests. Interpretation of thyroid disorders	MI-P SGD MI6.2 Gram staining- Interpretation of results
23.09.2023	SATURDAY	SUR-LDevelopmental anomalies of face, mouth and jaws SU19.1 Describe the etiology and classification of cleft lip and palate SU19.2 Describe the Principles of reconstruction of cleft lip and palate	PH-L 1.37 Describe the mechanisms of action,types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones 11-12 MED-L IM 23.1, 23.4 utritional assessment, enteral and parenteral nutrition	MI-P Integration MI5.1Meningitis-pyogenic (General Medicine) (Pathology) (Paediatrics)	MI-L MI5.1 Meningitis-aseptic and fungal (General Medicine) (Pathology	PH- L -1.39 Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception
			12-1-OBG-L-Recurrent pregnancy loss			
24.09.2023				SUNDAY		
25.09.2023	MONDAY	PA-L PA33.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis. PA 33.2 Classify and describe the etiology,pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumours. PA 33.3 : Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features, complications and metastases of soft tissue tumours. PA 33.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features, complications of Paget's disease of the bone. PA 33.5 Classify and describe the etiology, pathogenesis, manifestations, radiologic and iaboratory features, diagnostic criteria and complications of Rehumatoid arthritis.	CLINICAL POSTING	PA-P SGD (Batch A + B) PA 32.5 Describe the etiology,genetics,pathogenesis,manifestations,laboratory and morphologic features of Hyperparathyroidism. PA 32.6 Describe the etiology, pathogenesis, manifestations, laboratoryfindings, morphologic features,complications and metastases of pancreatic cancer PA 32.7: Describe the etiology, pathogenesis, manifestations, laboratory findings,morphologic features, complications of Adrenal InsufficiencyPA 32.8: Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Cushing's syndrome.PA 32.9: Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Adrenal Neoplasms.	PH-P-(Batch A)3.5 To prepare and explain a list of P-Drug for given case / condition	PA-P SGD (Batch B)PA 10.4 Define and describe the pathogenesis and pathology of common bacterial,viral,protozoal and helminthic diseases.
26.09.2023	TUESDAY	PH-L 1.40 Describe mechanism of action, types, doses, side effects, indications and contraindications of 3. Drugs used in the treatment of infertility, and Drugs used in erectile dysfunction		PH-P - 1.39 SDL-8 Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception	A	LETCOM
27.09.2023	WEDNESDAY	PA-SDL PA33.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis. PA 33.2 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumours. PA 33.3 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features, complications and metastases of soft tissue tumours. PA 33.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features, complications of Paget's disease of the bone. PA 33.5 Classify and describe the etiology, pathogenesis, manifestations. radiologic and morphologic features, complications of Paget's disease of the bone. PA 33.5 Classify and describe the etiology, pathogenesis, manifestations, radiologic and		PH-1.39 SDL-8 Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception	PA-P SGD (Batch A) PA 23.2 Describe abornal findings in body fluids in various disease states. PA 23.3 (I V) Describe and interpret the abnormalities in Semen Analysis	MI-P SGD MI5.3 CSF- Interpretation of reports
28.09.2023	THURSDAY			EID-E-MILAD		

30.09.2023	FRIDAY	Mi-L Integration MI5.2 Encephalitis-parasitic and for (General Medicine) (Paediatrics) SUR-LOropharyngeal cancer	PH-L-1.41 Describe the mechanism s of action, types, doses, side effects	CM-P Immunization & Cold chain spotters demonstration MI-P Integration MI8.1 Zoonotic diseases I Bacterial1,	PA-P SGD(Batch B) PA 23.2 Describe abnormal findings in body fluids in various disease states. PA 23.3 (IV) Describe and interpret the abnormalities in Semen Analysis interpret the Analysis PA - Batch A + B REVISION.	MI-P SGD MI5.3 CSF- Interpretation of reports MI-L. Integration MI8.1 Zoonotic diseases 2 Bacterial2	
		SU20.1 Describe etiopathogenesis of oral cancer symptoms and signs of oropharyngeal cancer. SU20.2 Enumerate the appropriate investigations and discuss the Principles of treatment.	, indications and contra indications of uterine relaxants and stimulants 11-12 MED-L IM 23.2; 23.3 protein caloric malnutrition, vitamin deficiencies 12-1 OBG-L -OG-11.1-Multifetal pregnancy	Leptospira, Anthrax (General Medicine)		Brucella, Yesinia (General Medicine)	
				October-2023			
DATE	DAY	9:00-10:00	10:00-1:00	2:00-3:00	3:00-4:00	4:00-5:00	
01.10.2023			SUNDAY				
02.10.2023	MONDAY		GANDHI JAYANTI				
03.10.2023	TUESDAY	IInd INTERNAL ASSESSMENT EXAMINATION					
04.10.2023	WEDNESDAY		IIII INTERNAL ASSESSMENT EXAMINATION IIII INTERNAL ASSESSMENT EXAMINATION				
05.10.2023	THURSDAY			FERNAL ASSESSMENT EXAMINATION			
06.10.2023	FRIDAY		IInd INTERNAL ASSESSMENT EXAMINATION				
07.10.2023	SATURDAY	IInd INTERNAL ASSESSMENT EXAMINATION					
08.10.2023				SUNDAY			
09.10.2023	MONDAY	IInd INTERNAL ASSESSMENT EXAMINATION					
10.10.2023	TUESDAY	IInd INTERNAL ASSESSMENT EXAMINATION					
11.10.2023	WEDNESDAY		IInd INTERNAL ASSESSMENT EXAMINATION				
12.10.2023	THURSDAY	IInd INTERNAL ASSESSMENT EXAMINATION					
13.10.2023	FRIDAY		lind IN1	TERNAL ASSESSMENT EXAMINATION			
14.10.2023	SATURDAY		IInd IN1	TERNAL ASSESSMENT EXAMINATION			
15.10.2023			SUNDAY				
16.10.2023	MONDAY		lind INT	FERNAL ASSESSMENT EXAMINATION			
17.10.2023	TUESDAY		IInd INTERNAL ASSESSMENT EXAMINATION				
18.10.2023	WEDNESDAY	IInd INTERNAL ASSESSMENT EXAMINATION					

19.10.2023	THURSDAY	PH L -1.42 Describe general principles of chemotherapy "	CLINICAL POSTING	PH -P-T -1.42 Describe general principles of chemotherapY	MI-P Integration MI8.1 Zoonotic diseases3 Rabies (General Medicine) Zoonotic diseases/Demonstration of	PH-P P-3.6 (Batch A) Demonstrate how to optimize Interaction with pharmaceutical representative (Medical Representative) to get authentic information on drugs
20.10.2023	FRIDAY	MI-L Integration Mi8.1 Zoonotic diseases 4 Arboviruses (General Medicine		MI-P MI8.1 Zoonotic diseases 5 Parasitic (General Medicine)	PA-P SGD(Batch A) PA33.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis. PA 33.2 Classify and describe the etiology,pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumours. PA 33.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features, complications of Paget's disease of the bone. PA 33.5 Classify and describe the etiology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of Rheumatoid arthritis	PH-P P-3.6 (Batch B) Demonstrate how to optimize Interaction with pharmaceutical representative (Medical Representative) to get authentic information on drugs
21.10.2023	SATURDAY	MI-L Integration MI8.1 Vector borne diseases (PSN	FM12.1 SGD-21 Describe features and management of abuse/poisoning with following chemicals: Tobacco, cannabis, amphetamines, cocaine, hallucinogens, designer drugs & solvent		AETCOM	
22.10.2023				SUNDAY		
23.10.2023	MONDAY	PA-L. PA 34.1 Describe the risk factors,pathogenesis, pathology and natural history of Squamous Cell Carcinoma of the skin. PA 34.2 Describe the risk factors,pathogenesis, pathology and natural history of Basal Cell Carcinoma of the skin. PA34.3 Describe the distinguishing features between a nevus and melanoma. Describe the etiology, risk factors,pathogenesis, morphology, clinical features and metastases of Melanoma.	CLINICAL POSTING	MI-P SGD Integration MI8.5 Healthcare Associated Infections (HAI)/ MI8.7 Infection control practices and use of Personal Protective Equipments (PPE) (General Medicine) (PSM)(Surgery)	PH-P -1.62 (Batch A+B) SDL-9 Describe and di	cuss antiseptics and disinfectants
24.10.2023	TUESDAY			DUSSEHRA		
25.10.2023	WEDNESDAY	PH- L -1.42 Describe general principles of chemotherapy	CLINICAL POSTING	MI-P SGD Integration MI8.5 Healthcare Associated Infections (HAI)/ MI8.7 Infection control practices and use of Personal Protective Equipments (PPE) (General Medicine) (PSM)(Surgery)	PA-P SGD Batch B) PA33.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of osteomyelitis. PA 33.2 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumours. PA 33.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features, complications of Paget's disease of the bone. PA 33.5 Classify and describe the etiology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of Rheumatoid arthritis	PH-P(BATCH A) 3.1 Write rational, correct and legible generic prescription for a given condition and communicate to the same to the patient
26.10.2023	THURSDAY	PH -L-1.43 IM-4.23,MI-1.6 Describe and discuss the rational use of antimicrobials		PH-P T-1.43 IM-4.23,MI-1.6 Describe and discuss the rational use of antimicrobials	MI-P MI8.12 Discuss confidentiality pertaining to patient identity in laboratory results / MI8.15 Interpretation of laboratory reports(DOAP)	PH-P (BATCH A) 5.1 Communicate with the patient with empathy & ethics on all aspects of drug use
27.10.2023	FRIDAY	MI-L Integration MI.8.2 Opportunistic infections (General Medicine) (Pathology)		MI-P MI8.12 Discuss confidentiality pertaining to patient identity in laboratory results / MI8.15 Interpretation of laboratory reports(DOAP)	PA-P SGD (Batch A) PA33.3 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of soft tissue tumours.	PH-P (BATCH B) 5.1 Communicate with the patient with empathy & ethics on all aspects of drug use

28.10.2023	SATURDAY	MI-L Integration MI 8.3 Oncogenic Virususes (General Medicine) (Pathology)	FM-14.16 Practical:Skills in Forensic Medicine & Toxicology FM14.16 To examine & prepare medico-legal report of drunk person in a simulated/ supervised environment	AETCOM		
29.10.2023				SUNDAY		
30.10.2023	MONDAY	PA-L PA 35.1 Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis	CLINICAL POSTING	MI-P SGD Integration MI8.4 Describe the etiologic agents of emerging Infectious diseases (General Medicine)(PSM) SDL/PBL	PH-P 1.47 (Batch A+B) SDL-10- 1.51 on Descril adulterants, pollutants and insect repellents	e occupational and environmental pesticides, food
31.10.2023	TUESDAY	PA L PA 35.2 Classify and describe the etiology, genetics, pathogenesis, pathology, presentation sequelae and complications of CNS tumours.		CM-L CM 19.1, 19.2, 19.3 Essential medicines: Essential Medicine List, Essential medicines in primary health care, Counterfelt medicine & it's prevention	MI-P SGD Integration MI8.4 Describe the etiologic agents of emerging infectious diseases (General Medicine)(PSM) SDL/PBL	PH-P(BATCH B) 5.2 Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines
				November-2023		
DATE	DAY	9:00-10:00		2:00-3:00	3:00-4:00	4:00-5:00
01.11.2023	WEDNESDAY	PH -L - 1.43 IM-4.23,MI-1.6 Describe and discuss the rational use of antimicrobials	CLINICAL POSTING	MI-P SGD HAART regimen Case discussion	PA-P SGD(Batch B) PA33.3 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of soft tissue tumours.	PH- P (BATCH A) 5.2 Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines
02.11.2023	THURSDAY	PH -L-1.44 CT-1.14 Describe the firstlineantitubercular dugs, their mechanism s of action, side effects and doses		PH T-1.43 IM-4.23,MI-1.6 Describe and discuss the rational use of antimicrobials	MI-P HAND HYGEINE AND PPE	PH-P (BATCH A) 5.3 Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider
03.11.2023	FRIDAY	MI-L 16 National Health Programs in the prevention of common infectious diseases I		MI-P HAND HYGEINE AND PPE	PA-P SGD (Batch A) PA 34.1 Describe the risk factors, pathogenesis, pathology and natural history of Squamous Cell Carcinoma of the skin. PA 34.2 Describe the risk factors, pathogenesis, pathology and natural history of Basal Cell Carcinoma of the skin. PA34.3 Describe the distinguishing features between a nevus and melanoma. Describe the etiology, risk factors, pathogenesis, morphology, clinical features and metastases of Melanoma. PA 34.4 Identify, distinguish and describe common tumours of the skin.	PH-P (BATCH B) 5.3 Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider
04.11.2023	SATURDAY	MI-L 16 National Health Programs in the prevention of common infectious diseases I	CM-SDL CM 14.1 Conducting survey of Hospital waste segregation & disposal practices	PA-L+P BATCH A+ B PA 35.1 Describe the etiology, types and etiology,genetics, pathogenesis, pathology, presentation sequ parameters. Charts of Pyogenic, Tubercular and Viral meningit	elae and complications of CNS tumours. PA 35.3	 gs in meningitis.PA 35.2 Classify and describe the Identify the etiology of meningitis based on given CSF

06.11.2023	MONDAY	PA-SDL PA 36.1 Describe the etiology,genetics, pathogenesis, pathology, presentation,sequelae and complications of retinoblastoma	CLINICAL POSTING	MI-P SGD Gastrointestinal infections (diarrhea and dysentery) and their Lab diagnosis	PH-P 1.47 (Batch A+B) SDL-11 Describe the mindications and contraindications of the drugs helminthiasis	chanisms of action, types, doses, side effects, used in malaria, KALA- AZAR, Amebiasis and intestinal
07.11.2023	TUESDAY	PA-SDL PA32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings. PA32.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis. Pa32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/hypothyroidism. PA32.4 Classify and describe the epidemiology, etiology, pathogenesis, pathology, cli nical laboratory features, complications and procession of diabetes mellitus.		CM-L CM 13.1, 13.2, 13.3, 13.4 Disaster Management	MI-P SGD Gastrointestinal infections (diarrhea and dysentery) and their Lab diagnosis	PH-P (BATCH A) 5.3 + 5.4 Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider
08.11.2023	WEDNESDAY	PH-L-1.45 CT-1.15,MI-6.1 Describe the dugs used in MDR and XDR Tuberculosis			PA-P SGD (Batch B) PA 34.1 Describe the risk factors,pathogenesis, pathology and natural history of Squamous Cell Carcinoma of the skin. PA 34.2 Describe the risk factors,pathogenesis, pathology and natural history of Basal Cell Carcinoma of the skin. PA34.3 Describe the distinguishing features between a nevus and melanoma. Describe the etiology, risk factors,pathogenesis, morphology, clinical features and metastases of Melanoma. PA 34.4 Identify,distinguish and describe common tumours of the skin.	PH-P (BATCH A) 5.3+ 5.4 Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider
09.11.2023	THURSDAY	PH 1-1.46 DR-9.5 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antileproticdrugs			MI-P LRTI (pneumonia, bronchitis, bronchiolitis etc) and their lab diagnosis	PH-P (BATCH A) 5.3+5.4 Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider
10.11.2023	FRIDAY	DIWALI VACATION				
11.11.2023	SATURDAY	DIWALI VACATION				
12.11.2023	SUNDAY	DIWALI VACATION (LAXMI PUJAN -	DIWALI)			
13.11.2023	MONDAY	DIWALI VACATION				
14.11.2023	TUESDAY	DIWALI VACATION (PADWAA)				
15.11.2023	WEDNESDAY	DIWALI VACATION (BHAUBIJ)				
16.11.2023	THURSDAY	DIWALI VACATION				
17.11.2023	FRIDAY	DIWALI VACATION				
18.11.2023	SATURDAY	DIWALI VACATION				
19.11.2023				SUNDAY		
20.11.2023	MONDAY	PA-SDL A 32.5 Describe the etiology, genetics, pathogenesis, manifestations, la boratory and morphologic features of Hyperparathyroidism. PA 32.6 Describe the etiology, pathogenesis, manifestations, laboratoryfindings, morphologic features, complications and metastases of pancreatic cancer PA 32.7: Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Adrenal Insufficiency.PA 32.8: Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Cushing's syndrome.PA 32.9: Describe the etiology, pathogenesis, manifestations, laboratory findings, morphologic features, complications of Adrenal Neoplasms.	CLINICAL POSTING	MI-P SGD UTI and its lab diagnosis		ion, types, doses, side effects, indications and KALA- AZAR, Amebiasis and intestinal helminthiasis
21.11.2023	TUESDAY	PA-L Autopsy: Indications and techniquies. Autopsy findings in Myocardial Infarction, Cirrhosis with portal hypertension, Millary tuberculosis		CM-L CM 14.1, 14.3 Hospital Waste Management	MI-P SGD UT and its lab diagnosis	PH-P (BATCH B) 5.5, PF-10.6,18.1 Demonstrate an understanding of the caution in prescribing drugs likely to produce dependence and recommend the line of management

22.11.2023	WEDNESDAY	PH- L 1.47 [M-4.22,MI-3.5 Describe the mechanisms of action, types, doses,side effects, indications and contraindications of the drugs used in malaria, KALA- AZAR, Amebiasis and intestinal helminthiasis		MI-P SGD UTI and its lab diagnosis	PA-P SGD REVISION I BATCH B	PH-P 5.5 (BATH A) PF-10.6,18.1 Demonstrate an understanding of the caution in prescribing drugs likely to produce dependence and recommend the line of management
23.11.2023	THURSDAY	PH- L 1.47 IM-4.22,MI-3.5 Describe the mechanisms of action, types, doses,side effects, indications and contraindications of the drugs used in malaria, KALA- AZAR, Amebiasis and intestinal helminthiasis		PH-T-1.47 IM-4.22.MI-3.5 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in maļaria, KALA-AZAR, Amebiasis and intestinal helminthiasis	MI-P Infections of CNS (meningitis, encephalitis,brain abscess) and their lab diagnosis	PH- P (BATCH A) 5.6 PS-18.1 Demonstrate ability to educate public & patients about various aspects of drug use including drug dependence and OTC drugs
24.11.2023	FRIDAY	MI-L Vehicles and vectors of communicable disease & zoonosis		MI-P Infections of CNS (meningitis, encephalitis,brain abscess) and their lab diagnosis	PA-P SGD REVISION I BATCH A	PH-P(BATCH B) 5.6 PS-18.1 Demonstrate ability to educate public & patients about various aspects of drug use including drug dependence and OTC drugs
25.11.2023	SATURDAY	MI-L Role of laboratory in cross infection, Nosocomial infections/outbreak/epidemic	CM- SDL CM 8.2 Library visit for journal review of Communicable diseases	MI-L+P Septicaemia and lab diagnosis of PUO		
26.11.2023				SUNDAY		
27.11.2023	MONDAY			GURUNANAK JAYANTI		
28.11.2023	TUESDAY	PA-L Autopsy findings in Bronchogenic Carcinoma, Renal Cell Carcinoma, Carcinoma of Stomach and Colon	CLINICAL POSTING	CM-L CM 2.1, 2.2, 2.3, 2.4, 2.5 Relationship of social and behavioural factors to health and disease	MI-P SGD STD and their lab diagnosis (genital ulcerative disease)	PH-P (BATCH B) 5.7,FM-4.27 Demonstrate an understanding of the legal and ethical aspects of prescribing drugs
29.11.2023	WEDNESDAY	PH L-1.48 MI-7.1 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/STD and viral diseases including HIV		MI-P SGD STD and their lab diagnosis (genital ulcerative disease)	PA-P SGD REVISION II BATCH B	PH-P (BATCH A)3.8 PCommunicate effectively with a Patient on the Proper use of prescribed medication
30.11.2023	THURSDAY	PH L 1.53 Describe heavy metal poisoning and chelating agents		PH-P T-1.48 MI-7.1 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV "	MI-P Eye infections and their lab diagnosis	PH-P (BATCH A)5.7.FM-4.27 Demonstrate an understanding of the legal and ethical aspects of prescribing drugs
				December-2023		
DATE	DAY	9:00-10:00		2:00-3:00	3:00-4:00	4:00-5:00
DATE	DAT	MI-LPreventive inoculations, immunomodulations, and immunotherapy	CLINICAL POSTING	HAND HYGEINE/PPE	PA-P SGD REVISION II BATCH A	PH-P (BATCH B) 3.8 PCommunicate effectively with a Patient on the Proper use of prescribed medication
01.12.2023	FRIDAY					
		MI-L National Health Programs in the prevention of common infectious diseases I	CM-SDL CM 8.2 Library visit for journal review of Non-Communicable diseases	PH-P (Batch A+B) Revision		
02.12.2023	SATURDAY					

03.12.2023		SUNDAY SUNDAY
04.12.2023	MONDAY	PRELIMINARY EXAMINATION
05.12.2023	TUESDAY	PRELIMINARY EXAMINATION
06.12.2023	WEDNESDAY	PRELIMINARY EXAMINATION
07.12.2023	THURSDAY	PRELIMINARY EXAMINATION
08.12.2023	FRIDAY	PRELIMINARY EXAMINATION
09.12.2023	SATURDAY	PRELIMINARY EXAMINATION
10.12.2023		SUNDAY
11.12.2023	MONDAY	PRELIMINARY EXAMINATION
12.12.2023	TUESDAY	PRELIMINARY EXAMINATION
13.12.2023	WEDNESDAY	PRELIMINARY EXAMINATION
14.12.2023	THURSDAY	PRELIMINARY EXAMINATION
15.12.2023	FRIDAY	SUPPLEMENTARY EXAMINATION
16.12.2023	SATURDAY	SUPPLEMENTARY EXAMINATION
17.12.2023		SUNDAY
18.12.2023	MONDAY	SUPPLEMENTARY EXAMINATION
19.12.2023	TUESDAY	SUPPLEMENTARY EXAMINATION
20.12.2023	WEDNESDAY	SUPPLEMENTARY EXAMINATION
21.12.2023	THURSDAY	SUPPLEMENTARY EXAMINATION
22.12.2023	FRIDAY	SUPPLEMENTARY EXAMINATION
23.12.2023	SATURDAY	SUPPLEMENTARY EXAMINATION
24.12.2023		SUNDAY
25.12.2023	MONDAY	CHRISTMAS